```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 18   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS  4  DEC 18   CA/CAplus patent kind codes updated
 NEWS  5  DEC 18   MARPAT to CA/CAplus accession number crossover limit increased
                   to 50,000
 NEWS  6  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS  7  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS  8  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  9  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 10  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS 11  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 12  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS 13  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS 14  JAN 29   PHAR reloaded with new search and display fields
 NEWS 15  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 16  FEB 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 17  FEB 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 18  FEB 23   KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 19  FEB 26   MEDLINE reloaded with enhancements
 NEWS 20  FEB 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 21  FEB 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 22  FEB 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 23  FEB 26   CAS Registry Number crossover limit increased from 10,000
                   to 300,000 in multiple databases
 NEWS 24  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 25  MAR 16   CASREACT coverage extended
 NEWS 26  MAR 20   MARPAT now updated daily
 NEWS 27  MAR 22   LWPI reloaded
 NEWS 28  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS 29  MAR 30   INPADOCDB will replace INPADOC on STN
 NEWS 30  APR 02   JICST-EPLUS removed from database clusters and STN

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2007 HIGHEST RN 929247-80-3
DICTIONARY FILE UPDATES: 5 APR 2007 HIGHEST RN 929247-80-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> e sildenafil/cn
E1            1     SILD (STREPTOCOCCUS PYOGENES GENE SILD)/CN
E2            1     SILDATE/CN
E3            1 --> SILDENAFIL/CN
E4            1     SILDENAFIL ACETATE/CN
E5            1     SILDENAFIL ASCORBATE/CN
E6            1     SILDENAFIL CITRATE/CN
E7            1     SILDENAFIL FUMARATE/CN
E8            1     SILDENAFIL HYDROBROMIDE/CN
E9            1     SILDENAFIL HYDROCHLORIDE/CN
E10           1     SILDENAFIL LACTATE/CN
E11           1     SILDENAFIL MALEATE/CN
E12           1     SILDENAFIL MESILATE/CN

=> s e3
L1            1 SILDENAFIL/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   139755-83-2  REGISTRY
ED   Entered STN:  20 Mar 1992
CN   7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[(4-methyl-1-
     piperazinyl)sulfonyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-  (CA INDEX
     NAME)
OTHER CA INDEX NAMES:
CN   1H-Pyrazolo[4,3-d]pyrimidine, piperazine deriv.
CN   Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-
     d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI)
OTHER NAMES:
CN   5-[2-Ethoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-
     1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
CN   Revatio
CN   Sildenafil
MF   C22 H30 N6 O4 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
       HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE,
       MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE,
       TOXCENTER, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:   WHO
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1113 REFERENCES IN FILE CA (1907 TO DATE)
24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1122 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e vardenafil/cn
E1            1      VARD/CN
E2            1      VARDAX/CN
E3            1  --> VARDENAFIL/CN
E4            1      VARDENAFIL DIHYDROCHLORIDE/CN
E5            1      VARDENAFIL HYDROCHLORIDE/CN
E6            1      VARDHAK/CN
E7            1      VARDHMAN/CN
E8            1      VAREBIAN/CN
E9            1      VARENICLINE/CN
E10           1      VARENICLINE TARTRATE/CN
E11           1      VARENNESITE/CN
E12           1      VARENNESITE ((MN0.5-1FE0-0.5)2NA8((OH)0.5-1CL0-0.5)2(SI2O5)5
                     .12H2O)/CN

=> s e3
L2            1 VARDENAFIL/CN

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   224785-90-4  REGISTRY
ED   Entered STN:  11 Jun 1999
CN   Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[2-ethoxy-5-[(4-ethyl-1-
     piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-
     f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl- (9CI)
OTHER NAMES:
CN   2-[2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl]-5-methyl-7-propyl-
     3H-imidazo[5,1-f][1,2,4]triazin-4-one
CN   Nuviva
CN   Vardenafil
MF   C23 H32 N6 O4 S
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
       CASREACT, CBNB, CHEMCATS, EMBASE, HSDB*, IMSPATENTS, IMSRESEARCH, IPA,
       MEDLINE, MRCK*, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

311 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
314 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e tadalafil/cn
E1            1      TADA3L PROTEIN (XENOPUS TROPICALIS CLONE MGC:79575 IMAGE:697
                     8809 GENE TADA3L)/CN
E2            1      TADAB/CN
E3            1 --> TADALAFIL/CN
E4            1      TADB/CN
E5            1      TADB (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE TA
                     DB)/CN
E6            1      TADB (VIBRIO PARAHAEMOLYTICUS STRAIN O3:K6 GENE VPA0725)/CN
E7            1      TADB PILUS ASSEMBLY PROTEIN (RHIZOBIUM ETLI STRAIN CFN 42 PL
                     ASMID P42E)/CN
E8            1      TADB PROTEIN (CHLOROBIUM TEPIDUM STRAIN TLS GENE TADB)/CN
E9            1      TADB-LIKE PROTEIN (PLASMID PBD2 GENE PBD2.017)/CN
E10           2      TADB-LIKE PROTEIN INVOLVED IN PILUS FORMATION AND/OR PROTEIN
                      SECRETION (VIBRIO FISCHERI STRAIN ES114)/CN
E11           1      TADC (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE TA
                     DC)/CN
E12           1      TADC (VIBRIO PARAHAEMOLYTICUS STRAIN O3:K6 GENE VPA0726)/CN

=> s e3
L3            1 TADALAFIL/CN

=> d

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   171596-29-5  REGISTRY
ED   Entered STN:  21 Dec 1995
CN   Pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-
     2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-
     2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans)-
OTHER NAMES:
CN   (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-
     methylenedioxyphenyl)pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
CN   (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-
     methylpyrazino [1',2':1,6]pyrido[3,4-b]indole-1,4-dione
CN   Cialis
CN   GF 196960
CN   IC 351
CN   ICOS 351
CN   Tadalafil
CN   Tildenafil
CN   UK 336017
FS   STEREOSEARCH
DR   240822-07-5, 282541-36-0
MF   C22 H19 N3 O4
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA,
       CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, EMBASE, HSDB*,
       IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR,
       PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.  Rotation (+).
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

393 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
399 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> file medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     22.05      22.26

FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

 FILE LAST UPDATED: 6 Apr 2007 (20070406/UP).  FILE COVERS 1950 TO DATE.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

     FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007
                E SILDENAFIL/CN
L1            1 S E3
                E VARDENAFIL/CN
L2            1 S E3
                E TADALAFIL/CN
L3            1 S E3

     FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

=> d l1
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:end

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

     (FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

     FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007
                E SILDENAFIL/CN
L1            1 S E3
                E VARDENAFIL/CN
L2            1 S E3
                E TADALAFIL/CN
L3            1 S E3

     FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007

=> s l1
```

```
L4          2323 L1

=> s l2
L5           247 L2

=> s l3
L6             0 L3

=> s (sildenafil or vardenafil or tadalafil)
          2913 SILDENAFIL
           384 VARDENAFIL
           414 TADALAFIL
L7        3219 (SILDENAFIL OR VARDENAFIL OR TADALAFIL)

=> s l4 or l5
L8        2450 L4 OR L5

=> s l7 or l8
L9        3219 L7 OR L8

=> s (clitoral stimul? or clitoral sensi? or female erect?)
           514 CLITORAL
        918548 STIMUL?
            23 CLITORAL STIMUL?
               (CLITORAL(W)STIMUL?)
           514 CLITORAL
        824345 SENSI?
             3 CLITORAL SENSI?
               (CLITORAL(W)SENSI?)
       4649628 FEMALE
         15371 ERECT?
             2 FEMALE ERECT?
               (FEMALE(W)ERECT?)
L10         28 (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)

=> s l9 and l10
L11          2 L9 AND L10

=> d 1-2

L11  ANSWER 1 OF 2     MEDLINE on STN
Full Text
AN   2004435495     MEDLINE
DN   PubMed ID: 15333581
TI   The neurovascular mechanism of clitoral erection: nitric oxide and
     cGMP-stimulated activation of BKCa channels.
AU   Gragasin Ferrante S; Michelakis Evangelos D; Hogan Angie; Moudgil Rohit;
     Hashimoto Kyoko; Wu Xichen; Bonnet Sandra; Haromy Al; Archer Stephen L
CS   Department of Medicine (Cardiology) and the Vascular Biology Group,
     University of Alberta, Edmonton, Canada.
NC   R01-HL071115 (NHLBI)
SO   The FASEB journal : official publication of the Federation of American
     Societies for Experimental Biology, (2004 Sep) Vol. 18, No. 12, pp.
     1382-91.
     Journal code: 8804484. E-ISSN: 1530-6860.
CY   United States
DT   (IN VITRO)
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA   English
FS   Priority Journals
EM   200504
ED   Entered STN: 3 Sep 2004
     Last Updated on STN: 6 Apr 2005
     Entered Medline: 5 Apr 2005

L11  ANSWER 2 OF 2     MEDLINE on STN
Full Text
AN   1999194034     MEDLINE
DN   PubMed ID: 10096370
TI   Safety and efficacy of sildenafil in postmenopausal women with sexual
```

dysfunction.
AU Kaplan S A; Reis R B; Kohn I J; Ikeguchi E F; Laor E; Te A E; Martins A C
CS Department of Urology, Columbia University, New York, New York 10032, USA.
SO Urology, (1999 Mar) Vol. 53, No. 3, pp. 481-6.
Journal code: 0366151. ISSN: 0090-4295.
CY United States
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199904
ED Entered STN: 4 May 1999
Last Updated on STN: 13 Jan 2000
Entered Medline: 22 Apr 1999

=> d an ti au so ab kwic 2

L11 ANSWER 2 OF 2 MEDLINE on STN
Full Text
AN 1999194034 MEDLINE
TI Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction.
AU Kaplan S A; Reis R B; Kohn I J; Ikeguchi E F; Laor E; Te A E; Martins A C
SO Urology, (1999 Mar) Vol. 53, No. 3, pp. 481-6.
Journal code: 0366151. ISSN: 0090-4295.
AB OBJECTIVES: **Sildenafil** has been demonstrated to be safe and effective in the treatment of men with erectile dysfunction. The role of **sildenafil** in treating women with sexual dysfunction has heretofore not been reported. The purpose of this preliminary study was to ascertain the response of postmenopausal women with self-described sexual dysfunction treated with **sildenafil** for 3 months. METHODS: Thirty-three consecutive postmenopausal women with sexual dysfunction based on history were entered in this open-label, nonrandomized study. All patients received 50 mg of **sildenafil**. Efficacy was assessed at weeks 4, 8, and 12 using a newly developed 9-item, self-administered Index of Female Sexual Function (IFSF) and a global efficacy question ([GEQ] Did treatment improve your sexual function?). The IFSF quantifies the domains of desire, quality of sexual intercourse, overall satisfaction with sexual function, orgasm, lubrication, and clitoral sensation. RESULTS: Of the group, 30 women (91 %) completed the study and were available for follow-up at 3 months. Mean baseline IFSF score before therapy was 24.8+/-9.8. Mean usage of **sildenafil** was 3.1+/-1.4 times per week for the duration of the study. The IFSF score improved to 29.5+/-7.6, 30.3+/-8.5, and 31.4+/-10.4 at 4, 8, and 12 weeks, respectively (P = 0.25). Mean scores for questions 2 (lubrication), 8 (orgasm), and 9 (clitoral sensation) improved by 23.2%, 7.4%, and 31.3%, respectively, at 12 weeks. Seven women (21%) noted improvement on the GEQ. Overall, only 6 (18.1%) of 33 patients had a significant (more than 60% improvement in IFSF score) therapeutic response. Clitoral discomfort and "hypersensitivity" occurred in 7 women (21%), 3 of whom withdrew from the study. Other side effects, which did not result in withdrawal from the study, included headache (n = 5), dizziness (n = 4) and dyspepsia (n = 3). CONCLUSIONS: The data suggest that **sildenafil** is well tolerated in postmenopausal women with sexual dysfunction. Overall sexual function did not improve significantly, although there were changes in vaginal lubrication and **clitoral sensitivity**. The role of **sildenafil** in treating sexual dysfunction in various cohorts of women remains to be determined.
TI Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction.
AB OBJECTIVES: **Sildenafil** has been demonstrated to be safe and effective in the treatment of men with erectile dysfunction. The role of **sildenafil** in treating women with sexual dysfunction has heretofore not been reported. The purpose of this preliminary study was to ascertain the response of postmenopausal women with self-described sexual dysfunction treated with **sildenafil** for 3 months. METHODS: Thirty-three consecutive postmenopausal women with sexual dysfunction based on history were entered in this open-label, nonrandomized study. All patients received 50 mg of **sildenafil**. Efficacy was assessed at weeks 4, 8, and 12 using a newly developed 9-item, self-administered Index of Female Sexual Function. . . study and were available for follow-up at 3 months. Mean baseline IFSF score before therapy was 24.8+/-9.8. Mean usage of **sildenafil** was

3.1+/-1.4 times per week for the duration of the study. The IFSF score improved to 29.5+/-7.6, 30.3+/-8.5, and 31.4+/-10.4. . . study, included headache (n = 5), dizziness (n = 4) and dyspepsia (n = 3). CONCLUSIONS: The data suggest that **sildenafil** is well tolerated in postmenopausal women with sexual dysfunction. Overall sexual function did not improve significantly, although there were changes in vaginal lubrication and **clitoral sensitivity**. The role of **sildenafil** in treating sexual dysfunction in various cohorts of women remains to be determined.
RN **139755-83-2 (sildenafil)**

```
=> file uspatall
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 3.23      25.49

FILE 'USPATFULL' ENTERED AT 21:08:06 ON 06 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 21:08:06 ON 06 APR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

     (FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

     FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007
                E SILDENAFIL/CN
L1            1 S E3
                E VARDENAFIL/CN
L2            1 S E3
                E TADALAFIL/CN
L3            1 S E3

     FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007
L4         2323 S L1
L5          247 S L2
L6            0 S L3
L7         3219 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)
L8         2450 S L4 OR L5
L9         3219 S L7 OR L8
L10          28 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)
L11           2 S L9 AND L10

     FILE 'USPATFULL, USPAT2' ENTERED AT 21:08:06 ON 06 APR 2007

=> s l1 or l2 or l3
L12         430 L1 OR L2 OR L3

=> s (sildenafil or vardenafil or tadalafil)
L13        2092 (SILDENAFIL OR VARDENAFIL OR TADALAFIL)

=> s (clitoral stimul? or clitoral sensi? or female erect?)
L14         188 (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)

=> s l12 or l13
L15        2151 L12 OR L13

=> s l14 and l15
L16          48 L14 AND L15

=> s (sildenafil or vardenafil or tadalafil)/clm
L17         406 (SILDENAFIL OR VARDENAFIL OR TADALAFIL)/CLM

=> s (clitoral stimul? or clitoral sensi? or female erect?)/clm
L18          25 (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)/CLM

=> s l12 or l17
L19         590 L12 OR L17

=> s l18 and l19
```

```
L20          1 L18 AND L19

=> d

L20  ANSWER 1 OF 1  USPATFULL on STN
Full Text
AN      2005:214622  USPATFULL
TI      Method of using a compound of menthol and L-arginine as a preparation
        for the topical delivery of vardenafil for the treatment of female
        sexual dysfunction
IN      Thompson, James M., Cincinnati, OH, UNITED STATES
        Thompson, Justin R., Cincinnati, OH, UNITED STATES
        Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
PI      US 2005186294        A1  20050825
AI      US 2005-105228       A1  20050413 (11)
RLI     Continuation-in-part of Ser. No. US 2003-731692, filed on 9 Dec 2003,
        PENDING Division of Ser. No. US 2001-4091, filed on 23 Oct 2001,
        GRANTED, Pat. No. US 6702733 Continuation of Ser. No. US 2000-520110,
        filed on 7 Mar 2000, GRANTED, Pat. No. US 6322493 Continuation-in-part
        of Ser. No. US 1999-469959, filed on 21 Dec 1999, ABANDONED
        Continuation-in-part of Ser. No. US 1999-414250, filed on 7 Oct 1999,
        GRANTED, Pat. No. US 6224541 Continuation-in-part of Ser. No. US
        1999-340227, filed on 1 Jul 1999, GRANTED, Pat. No. US 6179775
DT      Utility
FS      APPLICATION
LN.CNT 458
INCL    INCLM: 424/739.000
        INCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000
NCL     NCLM:  424/739.000
        NCLS:  424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000
IC      [7]
        ICM    A61K031-198
        ICS    A61M035-00; A61K035-78
        IPCI   A61K0031-198 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61M0035-00
               [ICS,7]; A61K0035-78 [ICS,7]
        IPCR   A61H0019-00 [I,C*]; A61H0019-00 [I,A]; A61K0009-00 [I,C*];
               A61K0009-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A];
               A61K0031-185 [I,C*]; A61K0031-198 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l16 1-48

L16  ANSWER 1 OF 48  USPATFULL on STN
Full Text
AN      2006:289260  USPATFULL
TI      Cyclopentapyridine and tetrahydroquinoline derivatives
IN      Lefker, Bruce A., Galas Ferry, CT, UNITED STATES
        Liu, Kevin K. -C., East Lyme, CT, UNITED STATES
        Chen, Hou, Salem, CT, UNITED STATES
        Coffey, Steven Blair, Pawcatuck, CT, UNITED STATES
PA      Pfizer. Inc (U.S. corporation)
PI      US 2006247254        A1  20061102
AI      US 2006-395327       A1  20060331 (11)
PRAI    US 2006-762159P      20060126 (60)
        US 2005-667184P      20050331 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3713
INCL    INCLM: 514/253.040
        INCLS: 544/362.000; 544/363.000; 514/253.060
NCL     NCLM:  514/253.040
        NCLS:  514/253.060; 544/362.000; 544/363.000
IC      IPCI   A61K0031-496 [I,A]; C07D0403-04 [I,A]; C07D0403-00 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 2 OF 48  USPATFULL on STN
Full Text
AN      2005:318125  USPATFULL
TI      Peroxide compounds for the prevention and treatment of sexual
        dysfunction in humans
IN      Buyuktimkin, Servet, Robbinsville, NJ, UNITED STATES
```

Buyuktimkin, Nadir, Robbinsville, NJ, UNITED STATES
Yeager, James L., Lake Forest, IL, UNITED STATES
PI US 2005276865 A1 20051215
AI US 2005-131520 A1 20050518 (11)
PRAI US 2004-572904P 20040520 (60)
DT Utility
FS APPLICATION
LN.CNT 1071
INCL INCLM: 424/616.000
INCLS: 514/568.000
NCL NCLM: 424/616.000
NCLS: 514/568.000
IC [7]
ICM A61K031-19
ICS A61K033-40
IPCI A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0033-40 [ICS,7]
IPCR A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61K0033-40 [I,C*]; A61K0033-40 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 48 USPATFULL on STN
Full Text
AN 2005:214622 USPATFULL
TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of **vardenafil** for the treatment of female sexual dysfunction
IN Thompson, James M., Cincinnati, OH, UNITED STATES
Thompson, Justin R., Cincinnati, OH, UNITED STATES
Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
PI US 2005186294 A1 20050825
AI US 2005-105228 A1 20050413 (11)
RLI Continuation-in-part of Ser. No. US 2003-731692, filed on 9 Dec 2003, PENDING Division of Ser. No. US 2001-4091, filed on 23 Oct 2001, GRANTED, Pat. No. US 6702733 Continuation of Ser. No. US 2000-520110, filed on 7 Mar 2000, GRANTED, Pat. No. US 6322493 Continuation-in-part of Ser. No. US 1999-469959, filed on 21 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414250, filed on 7 Oct 1999, GRANTED, Pat. No. US 6224541 Continuation-in-part of Ser. No. US 1999-340227, filed on 1 Jul 1999, GRANTED, Pat. No. US 6179775
DT Utility
FS APPLICATION
LN.CNT 458
INCL INCLM: 424/739.000
INCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000
NCL NCLM: 424/739.000
NCLS: 424/742.000; 424/745.000; 424/747.000; 514/565.000; 604/001.000
IC [7]
ICM A61K031-198
ICS A61M035-00; A61K035-78
IPCI A61K0031-198 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61M0035-00 [ICS,7]; A61K0035-78 [ICS,7]
IPCR A61H0019-00 [I,C*]; A61H0019-00 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-185 [I,C*]; A61K0031-198 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 48 USPATFULL on STN
Full Text
AN 2005:105565 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M. JR., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PA Pfizer Inc (U.S. corporation)
PI US 2005090503 A1 20050428
AI US 2004-922058 A1 20040819 (10)
RLI Division of Ser. No. US 2002-163881, filed on 5 Jun 2002, PENDING
PRAI US 2001-299953P 20010621 (60)

DT Utility
FS APPLICATION
LN.CNT 4033
INCL INCLM: 514/252.110
INCLS: 544/357.000
NCL NCLM: 514/252.110
NCLS: 544/357.000
IC [7]
ICM A61K031-497
ICS C07D043-14
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]; C07D0043-14 [ICS,7]
IPCR C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 48 USPATFULL on STN
Full Text
AN 2005:82051 USPATFULL
TI Compounds for the treatment of female sexual dysfunction
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PA Pfizer Inc. (non-U.S. corporation)
PI US 2005070499 A1 20050331
AI US 2003-686349 A1 20031015 (10)
RLI Division of Ser. No. US 2000-708392, filed on 8 Nov 2000, GRANTED, Pat. No. US 6734186
PRAI GB 1999-26437 19991108
GB 2000-4021 20000218
GB 2000-13001 20000526
GB 2000-16563 20000705
GB 2000-17141 20000712
US 2000-175161P 20000107 (60)
US 2000-192962P 20000329 (60)
US 2000-217479P 20000711 (60)
US 2000-221014P 20000727 (60)
US 2000-221093P 20000727 (60)
DT Utility
FS APPLICATION
LN.CNT 7202
INCL INCLM: 514/047.000
NCL NCLM: 514/047.000
IC [7]
ICM A61K031-7076
IPCI A61K0031-7076 [ICM,7]; A61K0031-7042 [ICM,7,C*]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-185 [I,C*]; A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C*]; A61K0031-352 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-52 [I,A]; A61K0031-55 [I,C*]; A61K0031-55 [I,A]; A61K0038-43 [I,C*]; A61K0038-46 [I,A]; C12Q0001-44 [I,C*]; C12Q0001-44 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-68 [I,C*]; G01N0033-68 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 48 USPATFULL on STN
Full Text
AN 2005:63614 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
PA Pfizer Inc (U.S. corporation)
PI US 2005054656 A1 20050310
AI US 2004-942346 A1 20040916 (10)
RLI Division of Ser. No. US 2002-156884, filed on 28 May 2002, GRANTED, Pat. No. US 6825198
PRAI US 2001-299953P 20010621 (60)
DT Utility

```
FS      APPLICATION
LN.CNT 3890
INCL    INCLM: 514/252.110
        INCLS: 514/252.140; 544/295.000; 544/357.000; 514/252.180; 514/252.190
NCL     NCLM:  514/252.110
        NCLS:  514/252.140; 514/252.180; 514/252.190; 544/295.000; 544/357.000
IC      [7]
        ICM    A61K031-497
        ICS    A61K031-506; C07D043-14
        IPCI   A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]; A61K0031-506
               [ICS,7]; C07D0043-14 [ICS,7]
        IPCR   A61P0025-00 [I,C*]; A61P0025-28 [I,A]; C07D0239-00 [I,C*];
               C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A];
               C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*];
               C07D0409-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 7 OF 48  USPATFULL on STN
Full Text
AN      2005:38129  USPATFULL
TI      5-HT receptor ligands and uses thereof
IN      Chiang, Phoebe, East Lyme, CT, UNITED STATES
        Novomisle, William A., Stonington, CT, UNITED STATES
        Welch, Willard M., JR., Mystic, CT, UNITED STATES
PA      Pfizer Inc (U.S. corporation)
PI      US 2005032809        A1  20050210
        US 6995159           B2  20060207
AI      US 2004-942345       A1  20040916 (10)
RLI     Division of Ser. No. US 2002-156884, filed on 28 May 2002, GRANTED, Pat.
        No. US 6825198
PRAI    US 2001-299953P      20010621 (60)
DT      Utility
FS      APPLICATION
LN.CNT 2990
INCL    INCLM: 514/252.110
        INCLS: 514/252.140; 544/295.000; 544/357.000
NCL     NCLM:  514/252.180; 514/252.110
        NCLS:  514/252.190; 514/252.200; 544/295.000; 514/252.140; 544/357.000
IC      [7]
        ICM    A61K031-497
        ICS    A61K031-506; C07D043-14
        IPCI   A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]; A61K0031-506
               [ICS,7]; C07D0043-14 [ICS,7]
        IPCI-2 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; C07D0403-00 [I,A]
        IPCR   A61P0025-00 [I,C*]; A61P0025-28 [I,A]; C07D0239-00 [I,C*];
               C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A];
               C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*];
               C07D0409-12 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A];
               C07D0403-00 [I,C]; C07D0403-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 8 OF 48  USPATFULL on STN
Full Text
AN      2005:24055  USPATFULL
TI      5-HT receptor ligands and uses thereof
IN      Chiang, Phoebe, East Lyme, CT, UNITED STATES
        Novomisle, William A., Stonington, CT, UNITED STATES
        Welch, Willard M., JR., Mystic, CT, UNITED STATES
        Guzman-Perez, Angel, Stonington, CT, UNITED STATES
        DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
        Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
        Liu, Kevin K., East Lyme, CT, UNITED STATES
PA      Pfizer Inc (U.S. corporation)
PI      US 2005020604        A1  20050127
AI      US 2004-922198       A1  20040819 (10)
RLI     Division of Ser. No. US 2002-163881, filed on 5 Jun 2002, PENDING
PRAI    US 2001-299953P      20010621 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4284
INCL    INCLM: 514/252.110
        INCLS: 544/357.000
```

NCL NCLM: 514/252.110
NCLS: 544/357.000
IC [7]
ICM A61K031-497
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]
IPCR C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*];
C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];
C07D0409-00 [I,C*]; C07D0409-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 48 USPATFULL on STN
Full Text
AN 2005:23998 USPATFULL
TI Compounds for the treatment of female sexual dysfunction
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PA Pfizer Inc. (non-U.S. corporation)
PI US 2005020547 A1 20050127
AI US 2003-686282 A1 20031015 (10)
RLI Division of Ser. No. US 2000-708392, filed on 8 Nov 2000, GRANTED, Pat. No. US 6734186
PRAI GB 1999-26437 19991108
GB 2000-4021 20000218
GB 2000-13001 20000526
GB 2000-16563 20000705
GB 2000-17141 20000712
US 2000-175161P 20000107 (60)
US 2000-192962P 20000329 (60)
US 2000-217479P 20000711 (60)
US 2000-221014P 20000727 (60)
US 2000-221093P 20000727 (60)
DT Utility
FS APPLICATION
LN.CNT 7195
INCL INCLM: 514/169.000
NCL NCLM: 514/169.000
IC [7]
ICM A61K031-56
IPCI A61K0031-56 [ICM,7]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-185 [I,C*];
A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C*];
A61K0031-352 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A];
A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C*];
A61K0031-4412 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A];
A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-52 [I,A];
A61K0031-55 [I,C*]; A61K0031-55 [I,A]; A61K0038-43 [I,C*];
A61K0038-46 [I,A]; C12Q0001-44 [I,C*]; C12Q0001-44 [I,A];
G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-53 [I,C*];
G01N0033-53 [I,A]; G01N0033-68 [I,C*]; G01N0033-68 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 48 USPATFULL on STN
Full Text
AN 2004:326954 USPATFULL
TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of a 5-phosphodiaesterase inhibitor for the treatment of female sexual dysfunction
IN Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
Thompson, James M., Cincinnati, OH, UNITED STATES
PI US 2004258774 A1 20041223
AI US 2004-803148 A1 20040317 (10)
RLI Continuation-in-part of Ser. No. US 2003-731692, filed on 9 Dec 2003, PENDING Division of Ser. No. US 2001-4091, filed on 23 Oct 2001, GRANTED, Pat. No. US 6702733 Continuation of Ser. No. US 2000-520110, filed on 7 Mar 2000, GRANTED, Pat. No. US 6322493 Continuation-in-part of Ser. No. US 1999-469959, filed on 21 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-414250, filed on 7 Oct 1999, GRANTED, Pat. No. US 6224541 Continuation-in-part of Ser. No. US 1999-340227, filed on 1 Jul 1999, GRANTED, Pat. No. US 6179775
DT Utility
FS APPLICATION
LN.CNT 124

INCL INCLM: 424/739.000
INCLS: 424/747.000; 424/742.000; 424/765.000; 514/565.000
NCL NCLM: 424/739.000
NCLS: 424/742.000; 424/747.000; 424/765.000; 514/565.000
IC [7]
ICM A61K035-78
IPCI A61K0035-78 [ICM,7]
IPCR A61H0019-00 [I,C*]; A61H0019-00 [I,A]; A61K0009-00 [I,C*];
A61K0009-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A];
A61K0031-185 [I,C*]; A61K0031-198 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 48 USPATFULL on STN
Full Text
AN 2004:321498 USPATFULL
TI Compounds for the treatment of female sexual dysfunction
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PA Pfizer Inc (non-U.S. corporation)
PI US 2004254153 A1 20041216
AI US 2003-686390 A1 20031015 (10)
RLI Division of Ser. No. US 2000-708392, filed on 8 Nov 2000, GRANTED, Pat. No. US 6734186
PRAI GB 1999-26437 19991108
GB 2000-4021 20000218
GB 2000-13001 20000526
GB 2000-16563 20000705
GB 2000-17141 20000712
US 2000-175161P 20000107 (60)
US 2000-192962P 20000329 (60)
US 2000-217479P 20000711 (60)
US 2000-221014P 20000727 (60)
US 2000-221093P 20000727 (60)
DT Utility
FS APPLICATION
LN.CNT 7207
INCL INCLM: 514/171.000
INCLS: 514/047.000
NCL NCLM: 514/171.000
NCLS: 514/047.000
IC [7]
ICM A61K031-56
ICS A61K031-7076
IPCI A61K0031-56 [ICM,7]; A61K0031-7076 [ICS,7]; A61K0031-7042 [ICS,7,C*]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-185 [I,C*];
A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C*];
A61K0031-352 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A];
A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C*];
A61K0031-4412 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A];
A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-52 [I,A];
A61K0031-55 [I,C*]; A61K0031-55 [I,A]; A61K0038-43 [I,C*];
A61K0038-46 [I,A]; C12Q0001-44 [I,C*]; C12Q0001-44 [I,A];
G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-53 [I,C*];
G01N0033-53 [I,A]; G01N0033-68 [I,C*]; G01N0033-68 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 48 USPATFULL on STN
Full Text
AN 2004:116764 USPATFULL
TI Compounds for the treatment of female sexual dysfunction
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6734186 B1 20040511
AI US 2000-708392 20001108 (9)
PRAI GB 1999-26437 19991108
GB 2000-4021 20000218
GB 2000-13001 20000526
GB 2000-16563 20000705
GB 2000-17141 20000712
US 2000-221093P 20000727 (60)

```
       US 2000-221014P     20000727 (60)
       US 2000-217479P     20000711 (60)
       US 2000-192962P     20000329 (60)
       US 2000-175161P     20000107 (60)
DT     Utility
FS     GRANTED
LN.CNT 7110
INCL   INCLM: 514/263.100
       INCLS: 544/224.000; 544/242.000
NCL    NCLM:  514/263.100
       NCLS:  544/224.000; 544/242.000
IC     [7]
       ICM    A01N043-90
       ICS    A61K031-52; C07D237-00; C07D237-02; C07D239-00
       IPCI   A01N0043-90 [ICM,7]; A61K0031-52 [ICS,7]; A61K0031-519
              [ICS,7,C*]; C07D0237-00 [ICS,7]; C07D0237-02 [ICS,7]; C07D0237-00
              [ICS,7,C*]; C07D0239-00 [ICS,7]
       IPCR   A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-185 [I,C*];
              A61K0031-192 [I,A]; A61K0031-195 [I,A]; A61K0031-352 [I,C*];
              A61K0031-352 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A];
              A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4412 [I,C*];
              A61K0031-4412 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A];
              A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-52 [I,A];
              A61K0031-55 [I,C*]; A61K0031-55 [I,A]; A61K0038-43 [I,C*];
              A61K0038-46 [I,A]; C12Q0001-44 [I,C*]; C12Q0001-44 [I,A];
              G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G01N0033-53 [I,C*];
              G01N0033-53 [I,A]; G01N0033-68 [I,C*]; G01N0033-68 [I,A]
EXF    514/258; 514/263.1; 544/262; 544/224; 544/242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 13 OF 48  USPATFULL on STN
Full Text
AN     2004:114715  USPATFULL
TI     Treatment of sexual dysfunction
IN     Gonzalez, Maria Isabel, Sandwich, UNITED KINGDOM
       Higginbottom, Michael, Sandwich, UNITED KINGDOM
       Naylor, Alisdair MArk, Sandwich, UNITED KINGDOM
       Pinnock, Robert Denham, Ann Arbor, MI, UNITED STATES
       Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM
       Stock, Herman Thijs, Sandwich, UNITED KINGDOM
       Van Der Graaf, Pieter Hadewijn, Sandwich, UNITED KINGDOM
       Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PI     US 2004087561       A1  20040506
AI     US 2003-416934      A1  20031204 (10)
       WO 2001-GB5018          20011114
PRAI   GB 2001-9910        20010423
       GB 2001-11037       20010504
       WO 2000-GB4380      20001117
DT     Utility
FS     APPLICATION
LN.CNT 5490
INCL   INCLM: 514/169.000
       INCLS: 514/288.000; 514/573.000; 514/567.000; 514/002.000; 424/094.630
NCL    NCLM:  514/169.000
       NCLS:  424/094.630; 514/002.000; 514/288.000; 514/567.000; 514/573.000
IC     [7]
       ICM    A61K038-00
       ICS    A61K031-56; A61K031-48; A61K031-198; A61K031-557
       IPCI   A61K0038-00 [ICM,7]; A61K0031-56 [ICS,7]; A61K0031-48 [ICS,7];
              A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-557
              [ICS,7]
       IPCR   A61K0031-165 [I,C*]; A61K0031-165 [I,A]; A61K0031-17 [I,C*];
              A61K0031-17 [I,A]; A61K0031-18 [I,C*]; A61K0031-18 [I,A];
              A61K0031-185 [I,C*]; A61K0031-196 [I,A]; A61K0031-395 [I,C*];
              A61K0031-395 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A];
              A61K0031-433 [I,C*]; A61K0031-433 [I,A]; A61K0031-4412 [I,C*];
              A61K0031-4412 [I,A]; A61K0031-4523 [I,C*]; A61K0031-454 [I,A];
              A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 14 OF 48  USPATFULL on STN
Full Text
```

AN 2004:83187 USPATFULL
TI Bombesin antagonists
IN Higginbottom, Michael, Sandwich, UNITED KINGDOM
Kesten, Suzanne Ross, Ann Arbor, MI, UNITED STATES
Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM
Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM
Rawson, David James, Sandwich, UNITED KINGDOM
Schelkun, Robert Michael, Ann Arbor, MI, UNITED STATES
Yuen, Po-Wai, Ann Arbor, MI, UNITED STATES
PA Pfizer Inc. (non-U.S. corporation)
PI US 2004063643 A1 20040401
AI US 2003-425758 A1 20030428 (10)
PRAI GB 2002-10239 20020503
US 2002-398132P 20020723 (60)
DT Utility
FS APPLICATION
LN.CNT 5369
INCL INCLM: 514/019.000
INCLS: 514/237.800; 514/357.000; 514/408.000; 544/159.000; 546/336.000; 548/561.000
NCL NCLM: 514/019.000
NCLS: 514/237.800; 514/357.000; 514/408.000; 544/159.000; 546/336.000; 548/561.000
IC [7]
ICM A61K038-04
ICS A61K031-537; A61K031-44; A61K031-40
IPCI A61K0038-04 [ICM,7]; A61K0031-537 [ICS,7]; A61K0031-44 [ICS,7]; A61K0031-40 [ICS,7]
IPCR C07C0275-00 [I,C*]; C07C0275-28 [I,A]; C07D0207-00 [I,C*]; C07D0207-335 [I,A]; C07D0211-00 [I,C*]; C07D0211-26 [I,A]; C07D0213-00 [I,C*]; C07D0213-38 [I,A]; C07D0213-40 [I,A]; C07D0213-56 [I,A]; C07D0213-65 [I,A]; C07D0213-85 [I,A]; C07D0233-00 [I,C*]; C07D0233-54 [I,A]; C07D0235-00 [I,C*]; C07D0235-14 [I,A]; C07D0239-00 [I,C*]; C07D0239-26 [I,A]; C07D0257-00 [I,C*]; C07D0257-04 [I,A]; C07D0277-00 [I,C*]; C07D0277-64 [I,A]; C07D0295-00 [I,C*]; C07D0295-182 [I,A]; C07D0295-185 [I,A]; C07D0309-00 [I,C*]; C07D0309-04 [I,A]; C07D0333-00 [I,C*]; C07D0333-20 [I,A]; C07D0333-58 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-04 [I,A]; C07D0405-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]; C07D0413-00 [I,C*]; C07D0413-12 [I,A]; C07D0417-00 [I,C*]; C07D0417-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 48 USPATFULL on STN
Full Text
AN 2004:77410 USPATFULL
TI Method of colpoplasty
IN Matlock, David L., Los Angeles, CA, UNITED STATES
PI US 2004059190 A1 20040325
AI US 2003-461894 A1 20030613 (10)
PRAI US 2002-394947P 20020708 (60)
DT Utility
FS APPLICATION
LN.CNT 1095
INCL INCLM: 600/038.000
NCL NCLM: 600/038.000
IC [7]
ICM A61F005-00
IPCI A61F0005-00 [ICM,7]
IPCR A61B [I,S]; A61F0005-00 [I,C*]; A61F0005-00 [I,A]; A61K0031-575 [I,C*]; A61K0031-575 [I,A]

L16 ANSWER 16 OF 48 USPATFULL on STN
Full Text
AN 2004:19457 USPATFULL
TI Treatment of female sexual dysfunction with phosphodiesterase inhibitors
IN Place, Virgil A., Kawaihae, HI, UNITED STATES
Wilson, Leland F., Menlo Park, CA, UNITED STATES
Doherty, Paul C., JR., Cupertino, CA, UNITED STATES
Hanamoto, Mark S., Belmont, CA, UNITED STATES
Spivack, Alfred P., Menlo Park, CA, UNITED STATES

Gesundheit, Neil, Los Altos, CA, UNITED STATES
Bennett, Sean R., Denver, CO, UNITED STATES
Doherty, Jane, Cupertino, CA, UNITED STATES LR
PI US 2004014761 A1 20040122
AI US 2002-279039 A1 20021022 (10)
RLI Continuation-in-part of Ser. No. US 2000-499959, filed on 8 Feb 2000, GRANTED, Pat. No. US 6469016 Division of Ser. No. US 1998-181316, filed on 27 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-959064, filed on 28 Oct 1997, GRANTED, Pat. No. US 5877216 Continuation-in-part of Ser. No. US 1997-959057, filed on 28 Oct 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1429
INCL INCLM: 514/247.000
INCLS: 514/259.410; 514/264.100; 514/314.000; 514/389.000; 514/255.060
NCL NCLM: 514/247.000
NCLS: 514/255.060; 514/259.410; 514/264.100; 514/314.000; 514/389.000
IC [7]
ICM A61K031-519
ICS A61K031-4965; A61K031-50; A61K031-4709
IPCI A61K0031-519 [ICM,7]; A61K0031-4965 [ICS,7]; A61K0031-50 [ICS,7]; A61K0031-4709 [ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0009-02 [I,C*]; A61K0009-02 [I,A]; A61K0009-127 [I,C*]; A61K0009-127 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-15 [I,C*]; A61K0031-15 [I,A]; A61K0031-21 [I,C*]; A61K0031-21 [I,A]; A61K0031-28 [I,C*]; A61K0031-295 [I,A]; A61K0031-4164 [I,C*]; A61K0031-4178 [I,A]; A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4427 [I,A]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4704 [I,C*]; A61K0031-4704 [I,A]; A61K0031-48 [I,C*]; A61K0031-48 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A]; A61K0031-501 [I,C*]; A61K0031-501 [I,A]; A61K0031-502 [I,C*]; A61K0031-502 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A]; A61K0031-5375 [I,C*]; A61K0031-5377 [I,A]; A61K0031-538 [I,A]; A61K0031-557 [I,C*]; A61K0031-557 [I,A]; A61K0031-5575 [I,A]; A61K0031-5585 [I,A]; A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 48 USPATFULL on STN
Full Text
AN 2003:325098 USPATFULL
TI Indole derivatives as pde5-inhibitors
IN Orme, Mark W, Seattle, WA, UNITED STATES
Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES
Schultze, Lisa M, Woodinville, WA, UNITED STATES
PI US 2003229080 A1 20031211
US 6878711 B2 20050412
AI US 2003-398720 A1 20030409 (10)
WO 2001-US31364 20011009
DT Utility
FS APPLICATION
LN.CNT 987
INCL INCLM: 514/222.800
INCLS: 514/249.000; 544/009.000; 544/343.000
NCL NCLM: 514/250.000; 514/222.800
NCLS: 544/005.000; 544/009.000; 544/342.000; 544/343.000; 514/249.000
IC [7]
ICM A61K031-549
ICS C07D498-14; A61K031-498; C07D487-14
IPCI A61K0031-549 [ICM,7]; C07D0498-14 [ICS,7]; C07D0498-00 [ICS,7,C*]; A61K0031-498 [ICS,7]; C07D0487-14 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-14 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C*]; A61K0031-4985 [ICS,7]; A61P0015-10 [ICS,7]; A61P0015-00 [ICS,7,C*]
IPCR A61K0031-498 [I,C*]; A61K0031-498 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0513-00 [I,C*]; C07D0513-14 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 48 USPATFULL on STN
Full Text
AN 2003:300913 USPATFULL
TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness
IN Neal, Gary W., Knoxville, TN, UNITED STATES
PI US 2003212139 A1 20031113
AI US 2003-412555 A1 20030411 (10)
RLI Division of Ser. No. US 2001-880188, filed on 12 Jun 2001, GRANTED, Pat. No. US 6593369 Continuation of Ser. No. US 1999-391412, filed on 8 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-954122, filed on 20 Oct 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1248
INCL INCLM: 514/573.000
INCLS: 514/530.000
NCL NCLM: 514/573.000
NCLS: 514/530.000
IC [7]
ICM A61K031-557
IPCI A61K0031-557 [ICM,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-557 [I,C*]; A61K0031-557 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 48 USPATFULL on STN
Full Text
AN 2003:294885 USPATFULL
TI 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction
IN Wei, Edward T., Berkeley, CA, UNITED STATES
PI US 2003207903 A1 20031106
AI US 2002-191481 A1 20020708 (10)
RLI Continuation-in-part of Ser. No. US 2002-139193, filed on 2 May 2002, PENDING
DT Utility
FS APPLICATION
LN.CNT 721
INCL INCLM: 514/269.000
NCL NCLM: 514/269.000
IC [7]
ICM A61K031-513
IPCI A61K0031-513 [ICM,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-513 [I,C*]; A61K0031-513 [I,A]; A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0031-57 [I,C*]; A61K0031-573 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61M0015-08 [N,C*]; A61M0015-08 [N,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 48 USPATFULL on STN
Full Text
AN 2003:294873 USPATFULL
TI Combination therapy for modulating the human sexual response
IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES
PA Zonagen, Inc. (U.S. corporation)
PI US 2003207891 A1 20031106
AI US 2003-462888 A1 20030617 (10)
RLI Continuation of Ser. No. US 2000-717955, filed on 21 Nov 2000, ABANDONED Continuation of Ser. No. US 2000-403623, filed on 1 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-US10230, filed on 19 May 1998, PENDING
PRAI US 1997-49947P 19970519 (60)
DT Utility
FS APPLICATION
LN.CNT 929
INCL INCLM: 514/252.160
INCLS: 514/408.000; 514/002.000
NCL NCLM: 514/252.160
NCLS: 514/002.000; 514/408.000
IC [7]

ICM A61K031-519
ICS A61K031-4172; A61K038-17
IPCI A61K0031-519 [ICM,7]; A61K0031-4172 [ICS,7]; A61K0031-4164 [ICS,7,C*]; A61K0038-17 [ICS,7]
IPCR A61K0031-505 [I,C*]; A61K0031-505 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 48 USPATFULL on STN
Full Text
AN 2003:271544 USPATFULL
TI Use of halogenated heterocyclic compounds in the treatment of sexual dysfunction and cardiovascular disease
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES
PA R.T. Alamo Ventures I, LLC, Beverly Hills, CA (U.S. corporation)
PI US 2003191152 A1 20031009
US 7041677 B2 20060509
AI US 2002-282286 A1 20021028 (10)
PRAI US 2002-403033P 20020813 (60)
US 2002-361150P 20020301 (60)
US 2002-361146P 20020301 (60)
US 2002-360829P 20020301 (60)
US 2002-360954P 20020301 (60)
DT Utility
FS APPLICATION
LN.CNT 3811
INCL INCLM: 514/312.000
NCL NCLM: 514/312.000
NCLS: 514/299.000; 514/305.000; 514/306.000; 514/307.000; 514/311.000; 514/708.000
IC [7]
ICM A61K031-47
IPCI A61K0031-47 [ICM,7]
IPCI-2 A61K0031-47 [I,A]; A61K0031-44 [I,A]; A61K0031-41 [I,A]
IPCR A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-47 [I,A]; A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]; A61K0031-47 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 22 OF 48 USPATFULL on STN
Full Text
AN 2003:181501 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PI US 2003125334 A1 20030703
US 6894050 B2 20050517
AI US 2002-163881 A1 20020605 (10)
PRAI US 2001-299953P 20010621 (60)
DT Utility
FS APPLICATION
LN.CNT 5231
INCL INCLM: 514/252.110
INCLS: 544/357.000
NCL NCLM: 514/252.110
NCLS: 544/357.000
IC [7]
ICM A61K031-497
ICS C07D043-04
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]; C07D0043-04 [ICS,7]
IPCI-2 C07D0241-20 [ICM,7]; C07D0241-00 [ICM,7,C*]; C07D0401-12 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0409-12 [ICS,7]; C07D0409-00 [ICS,7,C*]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*]; A61P0025-28 [ICS,7]; A61P0025-00 [ICS,7,C*]
IPCR C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];

C07D0409-00 [I,C*]; C07D0409-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 48 USPATFULL on STN
Full Text
AN 2003:153438 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
PI US 2003105106 A1 20030605
US 6825198 B2 20041130
AI US 2002-156884 A1 20020528 (10)
PRAI US 2001-299953P 20010621 (60)
DT Utility
FS APPLICATION
LN.CNT 3888
INCL INCLM: 514/252.110
INCLS: 514/252.140; 544/295.000; 544/357.000
NCL NCLM: 514/252.140; 514/252.110
NCLS: 544/295.000; 544/357.000
IC [7]
ICM A61K031-496
ICS C07D043-14; C07D043-04
IPCI A61K0031-496 [ICM,7]; C07D0043-14 [ICS,7]; C07D0043-04 [ICS,7]
IPCI-2 C07D0024-120 [ICM,7]; C07D0401-12 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0409-12 [ICS,7]; C07D0409-00 [ICS,7,C*]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*]; A61P0025-28 [ICS,7]; A61P0025-00 [ICS,7,C*]
IPCR A61P0025-00 [I,C*]; A61P0025-28 [I,A]; C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 48 USPATFULL on STN
Full Text
AN 2003:134652 USPATFULL
TI Novel alpha adrenergic agents
IN Miller, Duane D., Germantown, TN, UNITED STATES
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF
PI US 2003092741 A1 20030515
US 6919357 B2 20050719
AI US 2002-215547 A1 20020809 (10)
PRAI US 2001-311320P 20010810 (60)
DT Utility
FS APPLICATION
LN.CNT 719
INCL INCLM: 514/341.000
INCLS: 514/370.000; 514/397.000; 514/401.000; 514/402.000; 546/272.700; 548/190.000; 548/312.700; 548/312.100; 548/315.400; 548/314.700; 548/326.500
NCL NCLM: 514/400.000; 514/341.000
NCLS: 548/332.500; 514/370.000; 514/397.000; 514/401.000; 514/402.000; 546/272.700; 548/190.000; 548/312.100; 548/312.700; 548/314.700; 548/315.400; 548/326.500
IC [7]
ICM C07D417-02
ICS C07D403-02; C07D049-02; C07D045-02; A61K031-4439; A61K031-427; A61K031-4178
IPCI C07D0417-02 [ICM,7]; C07D0417-00 [ICM,7,C*]; C07D0403-02 [ICS,7]; C07D0403-00 [ICS,7,C*]; C07D0049-02 [ICS,7]; C07D0045-02 [ICS,7]; A61K0031-4439 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-427 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C*]
IPCI-2 A61K0031-4168 [ICM,7]; A61K0031-4164 [ICM,7,C*]; C07D0233-88 [ICS,7]; C07D0233-00 [ICS,7,C*]
IPCR A61K0031-4164 [I,C*]; A61K0031-4168 [I,A]; A61K0031-4178 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4427 [I,A]; C07D0233-00 [I,C*]; C07D0233-52 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 48 USPATFULL on STN

Full Text
AN 2003:4131 USPATFULL
TI Combination therapy for modulating the human sexual response
IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES
PA ZONAGEN, INC. (U.S. corporation)
PI US 2003004170 A1 20030102
AI US 2002-217575 A1 20020813 (10)
RLI Division of Ser. No. US 2000-403623, filed on 1 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-US10230, filed on 19 May 1998, PENDING
PRAI US 1997-49947P 19970519 (60)
DT Utility
FS APPLICATION
LN.CNT 927
INCL INCLM: 514/252.160
INCLS: 514/012.000; 514/401.000
NCL NCLM: 514/252.160
NCLS: 514/012.000; 514/401.000
IC [7]
ICM A61K038-17
ICS A61K031-519
IPCI A61K0038-17 [ICM,7]; A61K0031-519 [ICS,7]
IPCR A61K0031-505 [I,C*]; A61K0031-505 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 48 USPATFULL on STN
Full Text
AN 2002:338074 USPATFULL
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Heaton, Jeremy P. W., Gananoque, CANADA
Adams, Michael A., Kingston, CANADA
PI US 2002193442 A1 20021219
US 6756407 B2 20040629
AI US 2002-126933 A1 20020422 (10)
RLI Division of Ser. No. US 1999-336088, filed on 18 Jun 1999, GRANTED, Pat. No. US 6395744 Continuation-in-part of Ser. No. US 1998-102987, filed on 22 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1995-546498, filed on 20 Oct 1995, GRANTED, Pat. No. US 5770606 Continuation-in-part of Ser. No. US 1994-231250, filed on 22 Apr 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1068
INCL INCLM: 514/579.000
NCL NCLM: 514/573.000; 514/579.000
NCLS: 514/284.000; 514/772.600
IC [7]
ICM A61K031-13
IPCI A61K0031-13 [ICM,7]
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-557 [ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-403 [I,C*]; A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C*]; A61K0031-472 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]; A61K0031-48 [I,C*]; A61K0031-48 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-565 [I,C*]; A61K0031-565 [I,A]; A61K0038-10 [I,C*]; A61K0038-11 [I,A]; A61K0038-12 [I,C*]; A61K0038-12 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 48 USPATFULL on STN
Full Text
AN 2002:301556 USPATFULL
TI Treatment of sexual dysfunction
IN Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM
Higginbottom, Michael, Cambridge, UNITED KINGDOM
Stock, Herman Thijs, Wijchen, NETHERLANDS
Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM
Pinnock, Robert Denham, Cambridgshire, UNITED KINGDOM
Van Der Graaf, Pieter Hadewijn, Kent, UNITED KINGDOM
Naylor, Alisdair Mark, Kent, UNITED KINGDOM

Wayman, Christopher Peter, Kent, UNITED KINGDOM
PI US 2002169101 A1 20021114
AI US 2001-999284 A1 20011115 (9)
RLI Continuation-in-part of Ser. No. US 2001-759777, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-700165, filed on 9 Nov 2000, PENDING A 371 of International Ser. No. WO 2000-GB1787, filed on 10 May 2000, UNKNOWN
PRAI GB 2001-9910 20010423
GB 2001-11037 20010504
US 1999-133355P 19990510 (60)
DT Utility
FS APPLICATION
LN.CNT 5522
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM A61K031-00
IPCI A61K0031-00 [ICM,7]
IPCR A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-165 [I,C*]; A61K0031-165 [I,A]; A61K0031-17 [I,C*]; A61K0031-17 [I,A]; A61K0031-18 [I,C*]; A61K0031-18 [I,A]; A61K0031-185 [I,C*]; A61K0031-196 [I,A]; A61K0031-395 [I,C*]; A61K0031-395 [I,A]; A61K0031-4015 [I,C*]; A61K0031-4015 [I,A]; A61K0031-403 [I,C*]; A61K0031-404 [I,A]; A61K0031-433 [I,C*]; A61K0031-433 [I,A]; A61K0031-4412 [I,C*]; A61K0031-4412 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; A61K0031-444 [I,A]; A61K0031-4523 [I,C*]; A61K0031-454 [I,A]; A61K0031-565 [I,C*]; A61K0031-565 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 48 USPATFULL on STN
Full Text
AN 2002:295077 USPATFULL
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Heaton, Jeremy P. W., Kingston, CANADA
Adams, Michael A., Kingston, CANADA
PI US 2002165122 A1 20021107
AI US 2002-136387 A1 20020502 (10)
RLI Continuation of Ser. No. US 1998-102987, filed on 22 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1995-546498, filed on 20 Oct 1995, GRANTED, Pat. No. US 5770606 Continuation-in-part of Ser. No. US 1994-231250, filed on 22 Apr 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 717
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM A61K031-00
IPCI A61K0031-00 [ICM,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-403 [I,C*]; A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C*]; A61K0031-472 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]; A61K0031-48 [I,C*]; A61K0031-48 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-565 [I,C*]; A61K0031-565 [I,A]; A61K0038-10 [I,C*]; A61K0038-11 [I,A]; A61K0038-12 [I,C*]; A61K0038-12 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT..

L16 ANSWER 29 OF 48 USPATFULL on STN
Full Text
AN 2002:266337 USPATFULL
TI The treatment of sexual dysfunction with enantiomers
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES
Sramek, John, Irvine, CA, UNITED STATES
PA R.T. Alamo Ventures I, L.L.C., Beverly Hills, CA, UNITED STATES (U.S. corporation)
PI US 2002147217 A1 20021010
AI US 2001-770704 A1 20010126 (9)
DT Utility

```
FS      APPLICATION
LN.CNT 1198
INCL    INCLM: 514/314.000
NCL     NCLM:  514/314.000
IC      [7]
        ICM    A61K031-47
        IPCI   A61K0031-47 [ICM,7]
        IPCR   A61K0031-47 [I,C*]; A61K0031-47 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 30 OF 48  USPATFULL on STN
Full Text
AN      2002:262363  USPATFULL
TI      Carboline derivatives as cGMP phosphodiesterase inhibitors
IN      Bombrun, Agnes, Monnetier Mornex, FRANCE
        Gellibert, Fran.cedilla.oise, Paris Cedex, FRANCE
PA      ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI      US 6462047           B1  20021008
        WO 2000015639  20000323
AI      US 2001-744859           20010516 (9)
        WO 1998-EP6050           19980916
                                 20010516  PCT 371 date
DT      Utility
FS      GRANTED
LN.CNT 1490
INCL    INCLM: 514/253.030
        INCLS: 514/252.180; 514/256.000; 514/275.000; 514/292.000; 544/332.000;
               544/335.000; 544/361.000; 546/085.000
NCL     NCLM:  514/253.030
        NCLS:  514/252.180; 514/256.000; 514/275.000; 514/292.000; 544/332.000;
               544/335.000; 544/361.000; 546/085.000
IC      [7]
        ICM    A61K031-437
        ICS    A61K031-496; A61K031-506; C07D471-04; C07D239-02; C07D401-14
        IPCI   A61K0031-437 [ICM,7]; A61K0031-4353 [ICM,7,C*]; A61K0031-496
               [ICS,7]; A61K0031-506 [ICS,7]; C07D0471-04 [ICS,7]; C07D0471-00
               [ICS,7,C*]; C07D0239-02 [ICS,7]; C07D0239-00 [ICS,7,C*];
               C07D0401-14 [ICS,7]; C07D0401-00 [ICS,7,C*]
        IPCR   A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-4427 [I,C*];
               A61K0031-444 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
               A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61P0001-00 [I,C*];
               A61P0001-00 [I,A]; A61P0001-04 [I,A]; A61P0007-00 [I,C*];
               A61P0007-02 [I,A]; A61P0009-00 [I,C*]; A61P0009-10 [I,A];
               A61P0009-12 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A];
               A61P0011-02 [I,A]; A61P0011-06 [I,A]; A61P0013-00 [I,C*];
               A61P0013-12 [I,A]; A61P0015-00 [I,C*]; A61P0015-10 [I,A];
               A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*];
               A61P0029-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];
               A61P0037-00 [I,C*]; A61P0037-08 [I,A]; A61P0043-00 [I,C*];
               A61P0043-00 [I,A]; C07D0471-00 [I,C*]; C07D0471-04 [I,A]
EXF     514/292; 514/256; 514/275; 514/253.03; 514/252.18; 546/85; 544/361;
        544/332; 544/335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 31 OF 48  USPATFULL on STN
Full Text
AN      2002:243641  USPATFULL
TI      Treatment of erectile dysfunction
IN      Mills, Thomas M., Augusta, GA, UNITED STATES
        Wingard, Christopher J., Augusta, GA, UNITED STATES
        Webb, R. Clinton, Matinez, GA, UNITED STATES
        Lewis, Ronald W., Augusta, GA, UNITED STATES
        Chitaley, Kanchan, Augusta, GA, UNITED STATES
PI      US 2002132832        A1  20020919
AI      US 2002-40010        A1  20020104 (10)
PRAI    US 2001-260062P      20010105 (60)
        US 2001-267296P      20010208 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1386
INCL    INCLM: 514/352.000
NCL     NCLM:  514/352.000
```

```
IC      [7]
        ICM     A61K031-4409
        IPCI    A61K0031-4409 [ICM,7]
        IPCR    A61K0031-4409 [I,C*]; A61K0031-4409 [I,A]; A61K0045-00 [I,C*];
                A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 32 OF 48  USPATFULL on STN
Full Text
AN      2002:133870  USPATFULL
TI      Composition to boost libido
IN      Reyes, Joe, Troy, MI, UNITED STATES
PI      US 2002068728        A1  20020606
        US 6803060           B2  20041012
AI      US 2001-927995       A1  20010810 (9)
PRAI    US 2000-230656P      20000907 (60)
DT      Utility
FS      APPLICATION
LN.CNT 612
INCL    INCLM: 514/182.000
NCL     NCLM:  424/769.000; 514/182.000
        NCLS:  424/725.000; 424/757.000; 514/177.000; 514/178.000; 514/181.000;
               514/458.000; 514/561.000
IC      [7]
        ICM     A61K031-56
        IPCI    A61K0031-56 [ICM,7]
        IPCI-2 A61K0035-78 [ICM,7]; A61K0031-56 [ICS,7]; A61K0031-355 [ICS,7];
               A61K0031-352 [ICS,7,C*]; A61K0031-195 [ICS,7]; A61K0031-185
               [ICS,7,C*]
        IPCR    A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0045-00 [I,C*];
               A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 33 OF 48  USPATFULL on STN
Full Text
AN      2002:122643  USPATFULL
TI      Method and compositions for the treatment or amelioration of female
        sexual dysfunction
IN      Adams, Michael A., Kingston, CANADA
        Heaton, Jeremy P. W., Gananoque, CANADA
PA      Queen's University at Kingston, Kingston, CANADA (non-U.S. corporation)
PI      US 6395744           B1  20020528
AI      US 1999-336088           19990618 (9)
RLI     Continuation-in-part of Ser. No. US 1998-102987, filed on 22 Jun 1998
        Continuation-in-part of Ser. No. US 1995-546498, filed on 20 Oct 1995,
        now patented, Pat. No. US 5770606 Continuation-in-part of Ser. No. US
        1994-231250, filed on 22 Apr 1994, now abandoned
DT      Utility
FS      GRANTED
LN.CNT 1218
INCL    INCLM: 514/284.000
        INCLS: 514/573.000; 514/772.600
NCL     NCLM:  514/284.000
        NCLS:  514/573.000; 514/772.600
IC      [7]
        ICM     A61K031-44
        IPCI    A61K0031-44 [ICM,7]
        IPCR    A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-403 [I,C*];
                A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C*];
                A61K0031-472 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A];
                A61K0031-48 [I,C*]; A61K0031-48 [I,A]; A61K0031-485 [I,C*];
                A61K0031-485 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A];
                A61K0031-565 [I,C*]; A61K0031-565 [I,A]; A61K0038-10 [I,C*];
                A61K0038-11 [I,A]; A61K0038-12 [I,C*]; A61K0038-12 [I,A];
                A61K0049-00 [I,C*]; A61K0049-00 [I,A]
EXF     514/772.6; 514/284; 514/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16  ANSWER 34 OF 48  USPATFULL on STN
Full Text
AN      2002:8529  USPATFULL
TI      METHODS, COMPOSITIONS, AND KITS FOR ENHANCING FEMALE SEXUAL DESIRE AND
```

RESPONSIVENESS
IN NEAL, GARY W., KNOXVILLE, TN, UNITED STATES
PI US 2002004529 A1 20020110
AI US 1997-954122 A1 19971020 (8)
DT Utility
FS APPLICATION
LN.CNT 989
INCL INCLM: 514/573.000
NCL NCLM: 514/573.000
IC [7]
ICM A61K031-47
ICS A61K031-557; A61K031-19
IPCI A61K0031-47 [ICM,7]; A61K0031-557 [ICS,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
IPCR A61K0047-12 [I,C*]; A61K0047-12 [I,A]; A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-557 [I,C*]; A61K0031-557 [I,A]; A61K0031-5575 [I,A]; A61K0047-22 [I,C*]; A61K0047-22 [I,A]; A61P0015-00 [I,C*]; A61P0015-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 48 USPATFULL on STN
Full Text
AN 2001:212470 USPATFULL
TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness
IN Neal, Gary W., Knoxville, TN, United States
PI US 2001044467 A1 20011122
US 6593369 B2 20030715
AI US 2001-880188 A1 20010612 (9)
RLI Continuation of Ser. No. US 1999-391412, filed on 8 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-954122, filed on 20 Oct 1997, PENDING
DT Utility
FS APPLICATION
LN.CNT 1284
INCL INCLM: 514/573.000
INCLS: 514/530.000
NCL NCLM: 514/573.000
NCLS: 514/874.000; 514/530.000
IC [7]
ICM A61K031-5575
IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C*]
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-557 [ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-557 [I,C*]; A61K0031-557 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 48 USPATFULL on STN
Full Text
AN 2001:158350 USPATFULL
TI Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
IN Scott, Nathan Earl, 610 Laguna Rd., Fullerton, CA, United States 92835
PI US 6291528 B1 20010918
AI US 1999-422031 19991020 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US26609, filed on 15 Dec 1998 Continuation-in-part of Ser. No. US 1998-38378, filed on 11 Mar 1998, now patented, Pat. No. US 5962528 Continuation-in-part of Ser. No. US 1998-5087, filed on 9 Jan 1998, now abandoned Continuation-in-part of Ser. No. US 1997-992946, filed on 18 Dec 1997, now patented, Pat. No. US 5981593 Continuation-in-part of Ser. No. US 1993-90483, filed on 12 Jul 1993, now patented, Pat. No. US 5708031, issued on 13 Jan 1998 Continuation of Ser. No. US 1992-860107, filed on 30 Mar 1992, now abandoned Continuation of Ser. No. US 1991-725350, filed on 3 Jul 1991, now abandoned
DT Utility
FS GRANTED
LN.CNT 1054
INCL INCLM: 514/573.000
NCL NCLM: 514/573.000

IC [7]
ICM A61K031-5575
IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C*]
IPCR A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0031-557 [I,A];
A61K0031-557 [I,C*]; A61K0031-5575 [I,A]
EXF 514/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 48 USPATFULL on STN
Full Text
AN 2000:150177 USPATFULL
TI Chemical compounds
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France
LaBaudiniere, Richard Frederick, Collegeville, PA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 6143757 20001107
AI US 1998-154619 19980916 (9)
RLI Continuation-in-part of Ser. No. WO 1996-EP3023, filed on 11 Jul 1996
DT Utility
FS Granted
LN.CNT 1803
INCL INCLM: 514/285.000
INCLS: 514/277.000; 514/279.000; 514/284.000; 514/287.000; 514/359.000
NCL NCLM: 514/285.000
NCLS: 514/277.000; 514/279.000; 514/284.000; 514/287.000; 514/359.000
IC [7]
ICM A61K031-44
IPCI A61K0031-44 [ICM,7]
IPCR C07D0471-00 [I,C*]; C07D0471-14 [I,A]
EXF 514/277; 514/279; 514/284; 514/285; 514/287; 514/359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 48 USPATFULL on STN
Full Text
AN 2000:150166 USPATFULL
TI Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France
Gellibert, Francoise, Marly le Roi Cedex, France
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 6143746 20001107
AI US 1998-154051 19980916 (9)
RLI Continuation-in-part of Ser. No. WO 1995-EP183, filed on 19 Jan 1995, now patented, Pat. No. WO 5859006 which is a continuation-in-part of Ser. No. WO 1996-EP3025, filed on 11 Jul 1996, now patented, Pat. No. WO 5981527 which is a continuation-in-part of Ser. No. WO 1996-EP3024, filed on 11 Jul 1996
PRAI GB 1994-1090 19940121
GB 1995-14465 19950714
GB 1995-14474 19950714
DT Utility
FS Granted
LN.CNT 3174
INCL INCLM: 514/249.000
INCLS: 514/250.000; 514/292.000
NCL NCLM: 514/249.000
NCLS: 514/250.000; 514/292.000
IC [7]
ICM A61K031-50
IPCI A61K0031-50 [ICM,7]
IPCR C07D0471-00 [I,C*]; C07D0471-14 [I,A]
EXF 514/249; 514/250; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 48 USPATFULL on STN
Full Text
AN 2000:37808 USPATFULL
TI Carboline derivatives
IN Bombrun, Agnes, Paris, France
PA Icos Corporation, Bothell, WA, United States (U.S. corporation)
PI US 6043252 20000328
AI US 1998-154052 19980916 (9)

RLI Continuation-in-part of Ser. No. WO 1997-EP2277, filed on 5 May 1997
DT Utility
FS Granted
LN.CNT 4016
INCL INCLM: 514/292.000
INCLS: 546/085.000
NCL NCLM: 514/292.000
NCLS: 546/085.000
IC [7]
ICM A61K031-44
IPCI A61K0031-44 [ICM,7]
IPCR C07D0471-00 [I,C*]; C07D0471-04 [I,A]
EXF 514/292; 546/85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 40 OF 48 USPAT2 on STN
Full Text
AN 2005:38129 USPAT2
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Jr., Willard M., Mystic, CT, UNITED STATES
PA Pfizer Inc., New York, NY, UNITED STATES (U.S. corporation)
PI US 6995159 B2 20060207
AI US 2004-942345 20040916 (10)
RLI Division of Ser. No. US 2002-156884, filed on 28 May 2002, Pat. No. US 6825198
PRAI US 2001-299953P 20010621 (60)
DT Utility
FS GRANTED
LN.CNT 2931
INCL INCLM: 514/252.180
INCLS: 514/252.190; 514/252.200; 544/295.000
NCL NCLM: 514/252.180; 514/252.110
NCLS: 514/252.190; 514/252.200; 544/295.000; 514/252.140; 544/357.000
IC IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]; A61K0031-506 [ICS,7]; C07D0043-14 [ICS,7]
IPCI-2 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; C07D0403-00 [I,A]
IPCR A61P0025-00 [I,C*]; A61P0025-28 [I,A]; C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]; A61K0031-4965 [I,C]; A61K0031-497 [I,A]; C07D0403-00 [I,C]; C07D0403-00 [I,A]
EXF 514/252.18; 514/252.19; 514/252.2; 544/295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 41 OF 48 USPAT2 on STN
Full Text
AN 2003:325098 USPAT2
TI Indole derivatives as PDE5-inhibitors
IN Orme, Mark W., Seattle, WA, UNITED STATES
Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES
Schultze, Lisa M., Woodinville, WA, UNITED STATES
PA Lilly Icos LLC, Wilmington, DE, UNITED STATES (U.S. corporation)
PI US 6878711 B2 20050412
WO 2002036593 20020510
AI US 2003-398720 20011009 (10)
WO 2001-US31364 20011009
20030409 PCT 371 date
PRAI US 2000-246257P 20001106 (60)
DT Utility
FS GRANTED
LN.CNT 948
INCL INCLM: 514/250.000
INCLS: 544/343.000; 544/342.000; 544/009.000; 544/005.000
NCL NCLM: 514/250.000; 514/222.800
NCLS: 544/005.000; 544/009.000; 544/342.000; 544/343.000; 514/249.000
IC [7]
ICM C07D487-14
ICS C07D487-22; A61K031-4985; A61P015-10
IPCI A61K0031-549 [ICM,7]; C07D0498-14 [ICS,7]; C07D0498-00 [ICS,7,C*]; A61K0031-498 [ICS,7]; C07D0487-14 [ICS,7];

C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-14 [ICM,7]; C07D0487-22 [ICS,7]; C07D0487-00 [ICS,7,C*]; A61K0031-4985 [ICS,7]; A61P0015-10 [ICS,7]; A61P0015-00 [ICS,7,C*]
IPCR A61K0031-498 [I,C*]; A61K0031-498 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A]; C07D0471-00 [I,C*]; C07D0471-14 [I,A]; C07D0513-00 [I,C*]; C07D0513-14 [I,A]
EXF 544/343; 514/250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 42 OF 48 USPAT2 on STN
Full Text
AN 2003:271544 USPAT2
TI Use of monochloroflosequinan in the treatment of sexual dysfunction
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES
PA R.T. Alamo Ventures I, LLC, Beverly Hills, CA, UNITED STATES (U.S. corporation)
PI US 7041677 B2 20060509
AI US 2002-282286 20021028 (10)
PRAI US 2002-403033P 20020813 (60)
US 2002-361150P 20020301 (60)
US 2002-361146P 20020301 (60)
US 2002-360829P 20020301 (60)
US 2002-360954P 20020301 (60)
DT Utility
FS GRANTED
LN.CNT 3781
INCL INCLM: 514/312.000
INCLS: 514/311.000; 514/305.000; 514/708.000; 514/306.000; 514/307.000; 514/299.000
NCL NCLM: 514/312.000
NCLS: 514/299.000; 514/305.000; 514/306.000; 514/307.000; 514/311.000; 514/708.000
IC IPCI A61K0031-47 [ICM,7]
IPCI-2 A61K0031-47 [I,A]; A61K0031-44 [I,A]; A61K0031-41 [I,A]
IPCR A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-47 [I,A]; A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-44 [I,C]; A61K0031-44 [I,A]; A61K0031-47 [I,C]
EXF 514/305; 514/306; 514/299; 514/307; 514/311-708
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 48 USPAT2 on STN
Full Text
AN 2003:181501 USPAT2
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Jr., Willard M., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PA Pfizer Inc., New York, NY, UNITED STATES (U.S. corporation)
PI US 6894050 B2 20050517
AI US 2002-163881 20020605 (10)
PRAI US 2001-299953P 20010621 (60)
DT Utility
FS GRANTED
LN.CNT 4125
INCL INCLM: 514/252.110
INCLS: 544/357.000
NCL NCLM: 514/252.110
NCLS: 544/357.000
IC [7]
ICM C07D241-20
ICS C07D401-12; C07D409-12; A61K031-497; A61P025-28
IPCI A61K0031-497 [ICM,7]; A61K0031-4965 [ICM,7,C*]; C07D0043-04 [ICS,7]
IPCI-2 C07D0241-20 [ICM,7]; C07D0241-00 [ICM,7,C*]; C07D0401-12 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0409-12 [ICS,7]; C07D0409-00 [ICS,7,C*]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*]; A61P0025-28 [ICS,7]; A61P0025-00 [ICS,7,C*]

IPCR C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]
EXF 544/357; 514/252.11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 48 USPAT2 on STN
Full Text
AN 2003:153438 USPAT2
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, United States
Novomisle, William A., Stonington, CT, United States
Welch, Jr., Willard M., Mystic, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6825198 B2 20041130
AI US 2002-156884 20020528 (10)
PRAI US 2001-299953P 20010621 (60)
DT Utility
FS GRANTED
LN.CNT 3176
INCL INCLM: 514/252.140
INCLS: 544/295.000
NCL NCLM: 514/252.140; 514/252.110
NCLS: 544/295.000; 544/357.000
IC [7]
ICM C07D024-120
ICS C07D401-12; C07D409-12; A61K031-497; A61P025-28
IPCI A61K0031-496 [ICM,7]; C07D0043-14 [ICS,7]; C07D0043-04 [ICS,7]
IPCI-2 C07D0024-120 [ICM,7]; C07D0401-12 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0409-12 [ICS,7]; C07D0409-00 [ICS,7,C*]; A61K0031-497 [ICS,7]; A61K0031-4965 [ICS,7,C*]; A61P0025-28 [ICS,7]; A61P0025-00 [ICS,7,C*]
IPCR A61P0025-00 [I,C*]; A61P0025-28 [I,A]; C07D0239-00 [I,C*]; C07D0239-46 [I,A]; C07D0241-00 [I,C*]; C07D0241-20 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A]; C07D0409-00 [I,C*]; C07D0409-12 [I,A]
EXF 514/252.14; 544/295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 48 USPAT2 on STN
Full Text
AN 2003:134652 USPAT2
TI α adrenergic agents
IN Miller, Duane D., Germantown, TN, UNITED STATES
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF
PA Molecular Design International Inc., Memphis, TN, UNITED STATES (U.S. corporation)
PI US 6919357 B2 20050719
AI US 2002-215547 20020809 (10)
PRAI US 2001-311320P 20010810 (60)
DT Utility
FS GRANTED
LN.CNT 632
INCL INCLM: 514/332.500
INCLS: 548/332.500
NCL NCLM: 514/400.000; 514/341.000
NCLS: 548/332.500; 514/370.000; 514/397.000; 514/401.000; 514/402.000; 546/272.700; 548/190.000; 548/312.100; 548/312.700; 548/314.700; 548/315.400; 548/326.500
IC [7]
ICM A61K031-4168
ICS C07D233-88
IPCI C07D0417-02 [ICM,7]; C07D0417-00 [ICM,7,C*]; C07D0403-02 [ICS,7]; C07D0403-00 [ICS,7,C*]; C07D0049-02 [ICS,7]; C07D0045-02 [ICS,7]; A61K0031-4439 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-427 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164 [ICS,7,C*]
IPCI-2 A61K0031-4168 [ICM,7]; A61K0031-4164 [ICM,7,C*]; C07D0233-88 [ICS,7]; C07D0233-00 [ICS,7,C*]
IPCR A61K0031-4164 [I,C*]; A61K0031-4168 [I,A]; A61K0031-4178 [I,A]; A61K0031-427 [I,C*]; A61K0031-427 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4427 [I,A]; C07D0233-00 [I,C*]; C07D0233-52 [I,A]
EXF 548/332.5; 514/392

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 46 OF 48 USPAT2 on STN
Full Text
AN 2002:338074 USPAT2
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Heaton, Jeremy P. W., Gananoque, CANADA
Adams, Michael A., Kingston, CANADA
PA Queen's University at Kingston, Kingston, CANADA (non-U.S. corporation)
PI US 6756407 B2 20040629
AI US 2002-126933 20020422 (10)
RLI Division of Ser. No. US 1999-336088, filed on 18 Jun 1999, now patented, Pat. No. US 6395744 Continuation-in-part of Ser. No. US 1998-102987, filed on 22 Jun 1998
DT Utility
FS GRANTED
LN.CNT 1241
INCL INCLM: 514/573.000
INCLS: 514/284.000; 514/772.600
NCL NCLM: 514/573.000; 514/579.000
NCLS: 514/284.000; 514/772.600
IC [7]
ICM A61K031-19
ICS A61K031-557
IPCI A61K0031-13 [ICM,7]
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-557 [ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-403 [I,C*]; A61K0031-4045 [I,A]; A61K0031-405 [I,A]; A61K0031-472 [I,C*]; A61K0031-472 [I,A]; A61K0031-473 [I,C*]; A61K0031-473 [I,A]; A61K0031-48 [I,C*]; A61K0031-48 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-565 [I,C*]; A61K0031-565 [I,A]; A61K0038-10 [I,C*]; A61K0038-11 [I,A]; A61K0038-12 [I,C*]; A61K0038-12 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]
EXF 514/284; 514/573; 514/772.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 47 OF 48 USPAT2 on STN
Full Text
AN 2002:133870 USPAT2
TI Composition to boost libido
IN Reyes, Joe, 1175 Chicago Rd., Troy, MI, United States 48083
PI US 6803060 B2 20041012
AI US 2001-927995 20010810 (9)
PRAI US 2000-230656P 20000907 (60)
DT Utility
FS GRANTED
LN.CNT 579
INCL INCLM: 424/769.000
INCLS: 424/757.000; 424/725.000; 424/195.100; 514/177.000; 514/178.000; 514/181.000; 514/458.000; 514/561.000
NCL NCLM: 424/769.000; 514/182.000
NCLS: 424/725.000; 424/757.000; 514/177.000; 514/178.000; 514/181.000; 514/458.000; 514/561.000
IC [7]
ICM A61K035-78
ICS A61K031-56; A61K031-355; A61K031-195
IPCI A61K0031-56 [ICM,7]
IPCI-2 A61K0035-78 [ICM,7]; A61K0031-56 [ICS,7]; A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*]; A61K0031-195 [ICS,7]; A61K0031-185 [ICS,7,C*]
IPCR A61K0031-56 [I,C*]; A61K0031-56 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
EXF 514/177; 514/178; 514/181; 514/249; 514/256; 514/258; 514/257; 514/261; 514/262; 514/561; 514/458; 424/195.1; 424/769; 424/757; 424/725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 48 USPAT2 on STN
Full Text
AN 2001:212470 USPAT2

TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness
IN Neal, Gary W., Knoxville, TN, United States
PA Vivus, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 6593369 B2 20030715
AI US 2001-880188 20010612 (9)
RLI Continuation of Ser. No. US 1999-391412, filed on 8 Sep 1999
Continuation-in-part of Ser. No. US 1997-954122, filed on 20 Oct 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 1130
INCL INCLM: 514/573.000
INCLS: 514/874.000
NCL NCLM: 514/573.000
NCLS: 514/874.000; 514/530.000
IC [7]
ICM A61K031-19
ICS A61K031-557
IPCI A61K0031-5575 [ICM,7]; A61K0031-557 [ICM,7,C*]
IPCI-2 A61K0031-19 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-557 [ICS,7]
IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0031-557 [I,C*]; A61K0031-557 [I,A]
EXF 514/573; 514/874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d an ti in pi kwic 1-48

L20 ANSWER 1 OF 1 USPATFULL on STN
Full Text
AN 2005:214622 USPATFULL
TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of vardenafil for the treatment of female sexual dysfunction
IN Thompson, James M., Cincinnati, OH, UNITED STATES
Thompson, Justin R., Cincinnati, OH, UNITED STATES
Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
PI US 2005186294 A1 20050825
CLM What is claimed is:
1. A manual application from an applicator of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and **vardenafil**, wherein said combination is applicable manually to the clitoris.

. . . contains less than 10% menthol and said combination contains less than 10% L-arginine and said combination contains less than 10% **vardenafil**.

. . . cyclic GMP induced production, via the actions of menthol and L-arginine, and the inhibition of the cyclic GMP degradation, by **vardenafil** in said compound, to create said vasodilatation and stimulation of the female clitoris.

. . . stimulation of the female clitoris, as recited in claim 17, by the step of: decreasing the dosage of menthol/L-arginine and/or **vardenafil** when topically applied to the female clitoris, to achieve said effective vasodilatation and maximum stimulation of the female clitoris.

19. A method to stimulate the female clitoris by the step of: utilizing menthol as a vehicle for **vardenafil** transport across the mucous membrane into the clitoral corpus cavernosa.

. . . for the production of cyclic GMP to therefore maximize the vasodilatation of the clitoral corpus cavernosa by the actions of **vardenafil** to inhibit the enzymatic degradation of that cyclic GMP.

=> d an ti in pi kwic 1-48

L20 ANSWER 1 OF 1 USPATFULL on STN
Full Text
AN 2005:214622 USPATFULL
TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of vardenafil for the treatment of female sexual dysfunction
IN Thompson, James M., Cincinnati, OH, UNITED STATES
Thompson, Justin R., Cincinnati, OH, UNITED STATES
Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
PI US 2005186294 A1 20050825
CLM What is claimed is:
1. A manual application from an applicator of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and **vardenafil**, wherein said combination is applicable manually to the clitoris.

. . . contains less than 10% menthol and said combination contains less than 10% L-arginine and said combination contains less than 10% **vardenafil**.

. . . cyclic GMP induced production, via the actions of menthol and L-arginine, and the inhibition of the cyclic GMP degradation, by **vardenafil** in said compound, to create said vasodilatation and stimulation of the female clitoris.

. . . stimulation of the female clitoris, as recited in claim 17, by the step of: decreasing the dosage of menthol/L-arginine and/or **vardenafil** when topically applied to the female clitoris, to achieve said effective vasodilatation and maximum stimulation of the female clitoris.

19. A method to stimulate the female clitoris by the step of: utilizing menthol as a vehicle for **vardenafil** transport across the mucous membrane into the clitoral corpus cavernosa.

. . . for the production of cyclic GMP to therefore maximize the vasodilatation of the clitoral corpus cavernosa by the actions of **vardenafil** to inhibit the enzymatic degradation of that cyclic GMP.

```
=> d an ti in pi kwic 48
     1 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):end

=> d his

     (FILE 'HOME' ENTERED AT 21:02:01 ON 06 APR 2007)

     FILE 'REGISTRY' ENTERED AT 21:02:13 ON 06 APR 2007
                E SILDENAFIL/CN
L1              1 S E3
                E VARDENAFIL/CN
L2              1 S E3
                E TADALAFIL/CN
L3              1 S E3

     FILE 'MEDLINE' ENTERED AT 21:03:50 ON 06 APR 2007
L4           2323 S L1
L5            247 S L2
L6              0 S L3
L7           3219 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)
L8           2450 S L4 OR L5
L9           3219 S L7 OR L8
L10            28 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)
L11             2 S L9 AND L10

     FILE 'USPATFULL, USPAT2' ENTERED AT 21:08:06 ON 06 APR 2007
L12           430 S L1 OR L2 OR L3
L13          2092 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)
```

```
L14          188 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)
L15         2151 S L12 OR L13
L16           48 S L14 AND L15
L17          406 S (SILDENAFIL OR VARDENAFIL OR TADALAFIL)/CLM
L18           25 S (CLITORAL STIMUL? OR CLITORAL SENSI? OR FEMALE ERECT?)/CLM
L19          590 S L12 OR L17
L20            1 S L18 AND L19

=> d l16 an ti in pi kwic 1-48

L16  ANSWER 1 OF 48  USPATFULL on STN
Full Text
AN      2006:289260  USPATFULL
TI      Cyclopentapyridine and tetrahydroquinoline derivatives
IN      Lefker, Bruce A., Galas Ferry, CT, UNITED STATES
        Liu, Kevin K. -C., East Lyme, CT, UNITED STATES
        Chen, Hou, Salem, CT, UNITED STATES
        Coffey, Steven Blair, Pawcatuck, CT, UNITED STATES
PI      US 2006247254        A1  20061102
DETD     . . . to increased vaginal lubrication via plasma transudation,
        increased vaginal compliance (relaxation of vaginal smooth muscle) and
        increases in vaginal and clitoral sensitivity.
DETD     . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double
        blind placebo controlled study with crossover to assess effect of
        sildenafil on physiological parameters of the female sexual response.
        J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic.
        . .

L16  ANSWER 2 OF 48  USPATFULL on STN
Full Text
AN      2005:318125  USPATFULL
TI      Peroxide compounds for the prevention and treatment of sexual
        dysfunction in humans
IN      Buyuktimkin, Servet, Robbinsville, NJ, UNITED STATES
        Buyuktimkin, Nadir, Robbinsville, NJ, UNITED STATES
        Yeager, James L., Lake Forest, IL, UNITED STATES
PI      US 2005276865        A1  20051215
SUMM     . . . to injectable vasodilators (Caverject®, Edex®) to
        intraurethral inserts (Muse®) to the more recent introduction of
        oral phosphodiesterase inhibitors such as sildenafil citrate
        (Viagra®), tadalafil (Cialis®) and vardenafil
        (Levitra®). Injectable preparations and intraurethral devices can
        cause local irritation problems.
SUMM     . . . only part of what makes the sexual act enjoyable for the woman
        but also enhances her response to coitus upon clitoral stimulation.
        Clitoral stimulation can induce local autonomic and somatic reflexes
        causing vaginal vasocongestion, engorgement, and subsequent
        transudation, lubricating the introital canal making the. . .

L16  ANSWER 3 OF 48  USPATFULL on STN
Full Text
AN      2005:214622  USPATFULL
TI      Method of using a compound of menthol and L-arginine as a preparation
        for the topical delivery of vardenafil for the treatment of female
        sexual dysfunction
IN      Thompson, James M., Cincinnati, OH, UNITED STATES
        Thompson, Justin R., Cincinnati, OH, UNITED STATES
        Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
PI      US 2005186294        A1  20050825
TI      Method of using a compound of menthol and L-arginine as a preparation
        for the topical delivery of vardenafil for the treatment of female
        sexual dysfunction
AB      A manual application of a topical clitoral sensitizing compound
        combination in an applicator, consisting essentially of L-arginine and a
        cooling agent comprised of Menthol and vardenafil, wherein the
        combination is applicable manually to the clitoris.
SUMM     . . . "Composition and method of use in treating sexual dysfunction
        using cGMP-specific PDE-5 inhibitors," Niazi writes of the benefits of
        using sildenafil in combination with L-arginine for the treatment of
        sexual dysfunction. Applied Mar. 26, 2001, and issued Jan. 15, 2002,
        U.S.. . . the use of a 5-PDE inhibitor but does not reference a
        specific vehicle needed to carry a large molecule like sildenafil
```

across the mucous membrane into the corpus cavernosa. In U.S. Pat. No. 6,403,658, titled "Genital Vasodilitation," Niazi references **sildenafil** as a smooth muscle cell relaxant for increasing blood flow to the genitals.

SUMM . . . Inhibitors," writes of the potential benefit of using phosphodiesterase inhibitors for the treatment of female sexual dysfunction. This patent references **sildenafil** and **tadalafil** as two phosphodiesterase type-5 specific inhibitors that could be used.

SUMM **Vardenafil**

SUMM . . . molecule. Even when topically applied to the mucous membrane, which is more absorptive than hairy skin, the size of the **vardenafil** molecule, a 5 phosphodiesterase inhibitor, with a large molecular weight, 579.2 g/Mol, requires the aid of a vehicle, or absorbing. . .

SUMM **Vardenafil** is a potent 5 Phosphodiesterase Inhibitor, a molecule that blocks the degradation of cGMP by specifically binding to the catalytic site of 5 Phosphodiesterase molecules. Blount et al, in "Binding of Titrated **Sildenafil**, **Tadalafil**, or **Vardenafil** to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation," found that the "absolute potency values were similar for each inhibitor, and the relative potencies were **vardenafil>tadalafil>sildenafil**." **Vardenafil**, **sildenafil**, and **tadalafil** are a group of inhibitors that bind restrictively to the catalytic domain of 5 Phosphodiesterase; "all three inhibitors also bind. . . and K_D (binding isotherm) values for each of the three inhibitors and were found to be 41:2:1 and 13:2:1 for **vardenafil**, tadalifil and **sildenafil**, respectively. The higher potency of **vardenafil** is due to differences in its double ring molecular structure. Blount also reported that increases in temperature closer to the normal human body temperature led to "increased **vardenafil** binding in the presence of cGMP," for 30 degrees Celsius versus 4 degrees Celsius. In vitro testing performed by Blount's group has also confirmed 100% inhibition of 5 Phosphodiesterase activity by the **vardenafil** molecule, where at similar Molar concentrations **sildenafil** and tadalifil were only 85% and 75% respectively.

SUMM . . . vessels in the mucous membrane of the clitoral tissues and functions as a vehicle to facilitate the transport of the **vardenafil** and L-arginine across the mucous membrane. Menthol has been shown clinically to increase membrane permeability by 2-4 times and decrease. . . molecular weight 288.42 g/Mol (Kaplan Frischoff et al). This increased permeability from the Menthol component allows both the L-arginine and **vardenafil** to cross the membrane and enter the corpus cavemosa.

SUMM . . . be expected from the dual mechanisms of the menthol/L-arginine induction and fueling of cyclic GMP production, and then by the **vardenafil** inhibition of cyclic GMP degradation. In both of the above mechanisms, nitric oxide (NO), is the intermediate signaler, or messenger,. . . potent vasodilator but is readily degraded as described above. The duel mechanism of action of the combination of menthol/L-arginine and **vardenafil** can be accurately described as different front-end and back-end mechanisms of action. Both the front-end mechanism of action and the. . .

SUMM . . . enzyme, iNOS. The back-end mechanism of action is the PDE-5 inhibition by the action of the potent specific PDE-5 inhibitor, **vardenafil**. By combining the front-end and the back-end mechanisms of action together, multiple benefits can not only be expected, but confirmed by clinical trials using the topical menthol/L-arginine and **vardenafil** to increase blood flow to the clitoris and therefore increase in a woman's sexual responsiveness. One benefit of the combination. . .

SUMM . . . and somewhat obscure rationale, is the utilization of the synergistic duel mechanisms of the action of the menthol/L-arginine and the **vardenafil** to increase the effectiveness of the topical combination with each successive use. McCullough et al studied the effectiveness of oral **sildenafil** in men. Titled "Intercourse success rates with **sildenafil** citrate," McCullough found that **sildenafil** was only 54% effective after its first use to create a penile erection. By the eighth use, the effectiveness of **sildenafil** had increased to 86%. This effect, increased effectiveness with increased usage, is biochemically and physiologically explained by the increasing concentrations. . .

SUMM . . . oxide synthase enzyme concentrations can be expected to increase dramatically; even between the first and second use of the

topical menthol/L-arginine/**vardenafil** combination. This dramatic increase in nitric oxide synthase enzyme concentrations, counter acting the effects of aging, would be expected to. . . corpus cavemosa vasodilatation and maximize women's sexual responsiveness even with the second or third use of the topical combination of menthol/L-arginine/**vardenafil**.

SUMM . . . to the activity level of the nitric oxide synthase isoenzymes. A more specific medical reference relates the in-vitro pathway of **vardenafil** to accomplish vasodilatation and corpus cavemosa smooth muscle dilatation to effect a clitoral or penile erection. Dr. J S Kalsi et al in the February 2003 Journal of Urology reported that **vardenafil** resulted in concentration dependant relaxation of human and rabbit cavernosum in "BA741-2272, a novel nitric oxide independent soluble guanglate cyclase. . .

SUMM 2004 **Vardenafil** 1%/CSC vs. CSC Clinical Trial

SUMM Each woman was asked to use CSC at least 3 times and then use the **Vardenafil** 1%/CSC at least 3 times before reporting results

SUMM Percentage of Participants (n/N) Reporting an Increase in Rating over CSC

TABLE 2A*

Vardenafil 1%/CSC Percentage Rating Increase Over CSC (0-5); 2.5 = CSC

N=	Arousal	Lubrication. . . 16.3%	Speed to	Ease of Achieving	Orgasm	Multiple
40-49	45.5%		45.5%	81.8%	78.2%	27.3%
50-59	50.0%		55.0%	65.0%	75.0%	10.0%
Overall Avg	43.6%		45.4%	75.5%*	77.3%*	21.8%

*Esentially, all participants reported the **Vardenafil** 1%/CSC was a better product than the CSC alone to help achieve more intense orgasms

Combined Data: Added "Value" of **Vardenafil** 1% in the CSC Formula: (1+% Rating Inc over CSC)x% Participants Reporting Increase of V1 % CSC

SUMM 1. Lubrication speed and quality is not improved by **vardenafil** 1%/CSC over CSC

SUMM 2. Increased orgasm percentage and increased orgasm intensity are very significantly improved with the **vardenafil** 1%/CSC compared to the CSC alone

SUMM . . . is the ability to achieve a meaningful orgasm, and all of the validated instruments measure sexual satisfaction for FSD, the **vardenafil** 1%/CSC can be confidently predicted to establish efficacy over placebo with statistically significant results.

DETD . . . invention relates to a manually applicable topical preparation comprising a compound of menthol or a menthol substitute, and L-arginine, and **vardenafil** as that topical compound. This manually applicable compound is to be manually applied directly to a woman's clitoris, for the treatment of female sexual dysfunction. **Vardenafil** in one preferred embodiment may preferably comprise less than 10% of that topical compound.

DETD The invention thus comprises a manual application of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of menthol and **vardenafil** wherein the combination is applicable manually to the clitoris.

DETD . . . 10% menthol and the combination may contain less than 10% L-arginine and also the combination may contain less than 10% **vardenafil**.

CLM What is claimed is:

1. A manual application from an applicator of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and **vardenafil**, wherein said combination is applicable manually to the clitoris.

. . . contains less than 10% menthol and said combination contains less than 10% L-arginine and said combination contains less than 10% **vardenafil**.

. . . cyclic GMP induced production, via the actions of menthol and L-arginine, and the inhibition of the cyclic GMP degradation, by **vardenafil** in said compound, to create said vasodilatation and stimulation of the female clitoris.

. . . stimulation of the female clitoris, as recited in claim 17, by the step of: decreasing the dosage of menthol/L-arginine and/or **vardenafil** when topically applied to the female clitoris, to achieve said effective vasodilatation and maximum stimulation of the female clitoris.

19. A method to stimulate the female clitoris by the step of: utilizing menthol as a vehicle for **vardenafil** transport across the mucous membrane into the clitoral corpus cavernosa.

. . . for the production of cyclic GMP to therefore maximize the vasodilatation of the clitoral corpus cavernosa by the actions of **vardenafil** to inhibit the enzymatic degradation of that cyclic GMP.

L16 ANSWER 4 OF 48 USPATFULL on STN
Full Text
AN 2005:105565 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M. JR., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PI US 2005090503 A1 20050428
DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.
DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .
DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);
DETD (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .
DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and. . .
DETD According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.
DETD According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.
DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response.

J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 5 OF 48 USPATFULL on STN
Full Text
AN 2005:82051 USPATFULL
TI Compounds for the treatment of female sexual dysfunction
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PI US 2005070499 A1 20050331
SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **Sildenafil**), and prostaglandin (PGE_{1}--Alprostadil) that are injected or administered transurethrally in men, and topically to the genitalia in women.
SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital (e.g. vaginal and **clitoral**) **sensitivity**. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.
DETD . . . combination with one or more other pharmaceutically active agents, such as a P_{cGMP} (such a phosphodiesterase type 5 inhibitor eg **Sildenafil**, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg **sildenafil**, **vardenafil** (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.
DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.
DETD [1153] Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 6 OF 48 USPATFULL on STN
Full Text
AN 2005:63614 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
PI US 2005054656 A1 20050310
DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_{1}) that are injected or administered transurethrally in men and topically to the genitalia in women.
DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .
DETD [0233] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);
DETD [0236] (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .
DETD [0237] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and. . .

DETD . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 7 OF 48 USPATFULL on STN
Full Text

AN 2005:38129 USPATFULL

TI 5-HT receptor ligands and uses thereof

IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES

PI US 2005032809 A1 20050210
US 6995159 B2 20060207

DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.

DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .

DETD [0230] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD [0233] (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1':6, 1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .

DETD [0234] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f[]1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5, 1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);. . .

DETD . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 8 OF 48 USPATFULL on STN
Full Text

AN 2005:24055 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PI US 2005020604 A1 20050127
SUMM . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.
SUMM . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .
SUMM [0170] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)4-ethoxyphenyl]sulphonyl]4-methylpiperazine (see EP-A-0463756);
SUMM [0173] (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .
SUMM [0174] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);
SUMM [0176] According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
SUMM . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.
SUMM [0206] According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.
DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 9 OF 48 USPATFULL on STN
Full Text
AN 2005:23998 USPATFULL
TI Compounds for the treatment of female sexual dysfunction
IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM
PI US 2005020547 A1 20050127
SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **Sildenafil**), and prostaglandin (PGE_{1} Alprostadil) that are injected or administered transurethrally in men, and topically to the genitalia in women.
SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital (e.g. vaginal and **clitoral**) **sensitivity**. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.
DETD . . . combination with one or more other pharmaceutically active agents, such as a P_{cAMP} (such a phosphodiesterase type 5 inhibitor

eg **Sildenafil**, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg **sildenafil**, **vardenafil** (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.

DETD [1155] Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 10 OF 48 USPATFULL on STN
Full Text

AN 2004:326954 USPATFULL

TI Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of a 5-phosphodiaesterase inhibitor for the treatment of female sexual dysfunction

IN Thompson, Ronald J., Ft. Thomas, KY, UNITED STATES
Thompson, James M., Cincinnati, OH, UNITED STATES

PI US 2004258774 A1 20041223

AB A manual application of a topical **clitoral sensitizing** compound combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and a 5-phosphodiaesterase inhibitor, wherein the combination. . .

SUMM [0003] The compound **Sildenafil**, known by the trademark Viagra®, is a 5-phosphodiaesterase inhibitor that has proven to be a successful therapy for male erectile dysfunction. **Sildenafil** is an oral tablet. In a double-blind, placebo controlled clinical study of 583 women with diagnosed female sexual dysfunction; oral **sildenafil** was no more effective than a placebo. This study was conducted by Dr. Rosemary Basson.

SUMM [0004] Over several years, compounding pharmacists have attempted to develop a topical preparation of **sildenafil** to treat women with female sexual dysfunction, but this has proven less than effective because of the size of the **Sildenafil** molecule. Even when topically applied to the mucous membrane, which is more absorptive than hairy skin, the size of the **sildenafil** molecule requires the aid of a vehicle, or absorbing agent, to allow absorption of the **sildenafil** into the corpus cavernosa of the clitoris. The menthol component of the menthol/L-arginine combination acts as an immediate vasodilator of the vessels in the mucous membrane and functions as a lipophilic vehicle to facilitate the transport of the **Sildenafil** across the mucous membrane.

DETD [0009] The invention thus comprises a manual application of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and a 5-phosphodiaesterase inhibitor, wherein the combination is. . .

CLM What is claimed is:
1. A manual application of a topical **clitoral sensitizing** combination consisting essentially of L-arginine and a cooling agent comprised of Menthol and a 5-phosphodiaesterase inhibitor, wherein said combination is. . .

L16 ANSWER 11 OF 48 USPATFULL on STN
Full Text

AN 2004:321498 USPATFULL

TI Compounds for the treatment of female sexual dysfunction

IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM

PI US 2004254153 A1 20041216

SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **Sildenafil**), and prostaglandin ($PGE_{1\text{-}Alprostadil}$) that are injected or administered transurethrally in men, and topically to the genitalia in women.

SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased

genital (e.g. vaginal and **clitoral**) **sensitivity**. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.

DETD . . . combination with one or more other pharmaceutically active agents, such as a P_{cGMP} (such a phosphodiesterase type 5 inhibitor eg **Sildenafil**, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg **sildenafil**, **vardenafil** (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.

DETD [1158] Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction. Urology, 53, 481-486.

L16 ANSWER 12 OF 48 USPATFULL on STN
Full Text

AN 2004:116764 USPATFULL

TI Compounds for the treatment of female sexual dysfunction

IN Maw, Graham Nigel, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM

PI US 6734186 B1 20040511

SUMM . . . that promote circulation to the male genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, **Sildenafil**), and prostaglandin (PGE_{1}-Alprostadil) that are injected or administered transurethrally in men, and topically to the genitalia in women.

SUMM . . . engorgement. This will result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital (e.g. vaginal and **clitoral**) **sensitivity**. Hence, the present invention provides a means to restore, or potentiate, the normal sexual arousal response.

DETD . . . combination with one or more other pharmaceutically active agents, such as a P_{cGMP} (such a phosphodiesterase type 5 inhibitor eg **Sildenafil**, or a nitric oxide donor, or a nitric oxide precursor eg L-arginine or inhibitors of arginase) and/or a centrally acting. . . or in the alternative, the agent may be used in combination with one or more of: a PDE5 inhibitor (eg **sildenafil**, **vardenafil** (Bayer BA 38-9456) and IC351 (Cialis, Icos Lilly)), one or more of a nitric oxide donor (eg NMI-921), one or. . .

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.

DETD Kaplan, S. A., Reis, R. B., Kohm, I. J. et al. (1999). Safety and efficacy of **sildenafil** in postmenopausal women with sexual dysfunction. Urology, 53, 481486.

L16 ANSWER 13 OF 48 USPATFULL on STN
Full Text

AN 2004:114715 USPATFULL

TI Treatment of sexual dysfunction

IN Gonzalez, Maria Isabel, Sandwich, UNITED KINGDOM
Higginbottom, Michael, Sandwich, UNITED KINGDOM
Naylor, Alisdair MArk, Sandwich, UNITED KINGDOM
Pinnock, Robert Denham, Ann Arbor, MI, UNITED STATES
Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM
Stock, Herman Thijs, Sandwich, UNITED KINGDOM
Van Der Graaf, Pieter Hadewijn, Sandwich, UNITED KINGDOM
Wayman, Christopher Peter, Sandwich, UNITED KINGDOM

PI US 2004087561 A1 20040506

SUMM . . . be administered orally, therefore obviating the disadvantages

associated with i.c. administration. One such compound that is currently being manufactured is **sildenafil** (Viagra).

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**. Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of pre-, peri- and postmenopausal. . .

DETD . . . treatment of sexual dysfunction include alprostadil or phentolamine, NO (nitric oxide) enhancers such as L-arginine, and PDE5 inhibitors such as **sildenafil** or a pharmaceutically acceptable salt thereof (Scrip's Complete Guide to Women's Healthcare, p.194-205, 2000)(Sachs B. D., 2000, Benet and Melman,. . .

DETD [0457] 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1R-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD [0468] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433; and

DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.

IT 58-22-0, Testosterone 71-58-9, Medroxyprogesterone acetate 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 37221-79-7, Vasoactive intestinal peptide 37221-79-7D, Vasoactive intestinal peptide, analogs **139755-83-2**, Sildenafil 147676-53-7 **171596-29-5**, IC-351 215297-27-1 **224785-90-4**, Vardenafil 334826-98-1 334827-47-3 334827-59-7 335077-64-0 335077-70-8 389128-36-3
(treatment of male sexual dysfunction using neutral endopeptidase inhibitors and their combination with phosphodiesterase type 5 inhibitors and other agents in relation to inhibition of angiotensin converting enzyme)

L16 ANSWER 14 OF 48 USPATFULL on STN
Full Text
AN 2004:83187 USPATFULL
TI Bombesin antagonists
IN Higginbottom, Michael, Sandwich, UNITED KINGDOM
Kesten, Suzanne Ross, Ann Arbor, MI, UNITED STATES
Lewthwaite, Russell Andrew, Sandwich, UNITED KINGDOM
Pritchard, Martyn Clive, Sandwich, UNITED KINGDOM
Rawson, David James, Sandwich, UNITED KINGDOM
Schelkun, Robert Michael, Ann Arbor, MI, UNITED STATES
Yuen, Po-Wai, Ann Arbor, MI, UNITED STATES
PI US 2004063643 A1 20040401

DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men, and topically to the genitalia in women.

DETD [0425] Further suitable PDE5 inhibitors for the use according to the present invention include: 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]su lphonyl]-4-methylpiperazine (see EP-A-0463756); 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see EP-A-0526004); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO98/49166); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333); (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4',3-d]pyrimidin-7-one, also known as. . . 95 of published international application WO95/19978, as well as the compound of

examples 1, 3, 7 and 8; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433; and. . .

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 15 OF 48 USPATFULL on STN
Full Text
AN 2004:77410 USPATFULL
TI Method of colpoplasty
IN Matlock, David L., Los Angeles, CA, UNITED STATES
PI US 2004059190 A1 20040325

SUMM . . . on an understanding of the physiology of the male erectile response, recent advances in modern technology, including the commonly prescribed **sildenafil**, and recent interest in women's health issues, the study of female sexual dysfunction has gradually evolved. Study in this area. . .

DETD [0019] The term "climax" means orgasm whether by vulvar, vaginal, cervical or **clitoral stimulation**.

DETD . . . from the hypogastric plexus and the pelvic nerve and in which stimulation may result in climax apart from or including **clitoral stimulation**. It is understood that the anatomy of the GS area will be subject specific and may occupy varying locations and. . .

DETD . . . and/or testosterone cream for treatment of inhibited desire and/or vaginismus in pre-menopausal women. Potential benefits of this therapy include increased **clitoral sensitivity**, increased vaginal lubrication, increased libido, and heightened arousal. Potential side effects of testosterone administration, however, are significant, and whether topical. . .

DETD [0043] **Sildenafil**, the medication commonly known as Viagra®, serves to increase relaxation of clitoral and vaginal smooth muscle and blood flow to. . . J R, Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int. J. Impot. Res. 10: 84-90 (1998). **Sildenafil**, in combination with other vasoactive substances, may be used for treatment of female sexual arousal disorder. In combination with colpoplasty. . .

DETD [0044] Clinical studies evaluating safety and efficacy **sildenafil** in women with SAD are in progress. Several studies are already published demonstrating efficacy of **sildenafil** for treatment of FSD secondary to Serum Seratonin Reuptake Inhibitor (SSRI) use. Park K, Goldstein I, Andry C, et al:. . . and clitoral erectile insufficiency. Int. J. Impoten. Res. 9: 27-37 (1988); Nurnberg H G, Lodillo J, Hensley P, et al., **Sildenafil** for iatrogenic seratonergic antidepressant medication-inducted sexual dysfunction in 4 patients. J. Clin. Psych. 60(1): 33 (1999).

DETD . . . often during sexual intercourse does the subject reach climax
50.7% 82.7%
Time (min.) for does the subject to reach climax via **clitoral stimulation**
16.3 min 10.0 min.
Was subject ever able to reach climax through stimulation of GS area
(33.3%/no) (40.0%/unsure) (13.3%/no) (6.7%/unsure)
. . .

L16 ANSWER 16 OF 48 USPATFULL on STN
Full Text
AN 2004:19457 USPATFULL
TI Treatment of female sexual dysfunction with phosphodiesterase inhibitors
IN Place, Virgil A., Kawaihae, HI, UNITED STATES
Wilson, Leland F., Menlo Park, CA, UNITED STATES
Doherty, Paul C., JR., Cupertino, CA, UNITED STATES
Hanamoto, Mark S., Belmont, CA, UNITED STATES
Spivack, Alfred P., Menlo Park, CA, UNITED STATES
Gesundheit, Neil, Los Altos, CA, UNITED STATES

Bennett, Sean R., Denver, CO, UNITED STATES
Doherty, Jane, Cupertino, CA, UNITED STATES LR

PI US 2004014761 A1 20040122

SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile** tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .

SUMM . . . Seiyaku Co., Ltd.), particularly (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine, 2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]-pyrimidine, and (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine; zaprinast (1,4-dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one); 1-(3-chloroanilino)-4-phenylphthalazine (MY5445); dipyridamole, vinpocetine; FR229934 (Fujisawa Pharmaceutical Co., Ltd.); 1-methyl-3-isobutyl-8-(methylamino)xanthine; **tadalafil** (IC-351; Cialis®); **vardenafil** (Bayer); 4-aryl-1-isoquinolinone derivatives such as methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate dihydrochloride and the sulfate salt thereof (T-1032); 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid, monosodium. . .

SUMM [0041] Particularly preferred Type V phosphodiesterase inhibitors for use in conjunction with the present invention are **sildenafil** (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-dipyrimidin-7-one]), **tadalafil**, **vardenafil**, zaprinast, dipyridamole, and the compounds of WO 01/19802 to Aoyama, particularly those identified above.

SUMM . . . the physiological response to sexual stimulation such as, but not limited to, slowed, decreased or absent erectile response of the **female erectile** tissues; slowed, decrease or absent lubrication of the vagina; slowed decreased or absent ability to reach orgasm, and decreased intensity. . .

DETD [0096] A cream formulation is prepared for the topical administration of **sildenafil**. The cream includes the following components:

Sildenafil	500	mg
Beeswax	2.7	g
Carbopol ® 934 q.s. 100.0		g

DETD [0098] The procedure of Example 1 is repeated except that the following components are used:

Sildenafil	3.5	g
Polyethylene glycol 400	37.5	g
1,2,6-hexanetriol	20.0	g
Polyethylene glycol 4000 q.s.	100.0	g

DETD [0100] The procedure of Example 1 is repeated except that the following components are used:

Tadalafil	1.0	g
Polyethylene glycol 400	37.0	g
Polyethylene glycol 400 monostearate	26.0	g
Polyethylene glycol 4000 q.s.	100.0	g

DETD [0104] A vaginal suppository formulation is prepared for the administration of **sildenafil**. The suppository includes the following components:

Sildenafil	5.0	g
Polyethylene glycol 400	37.0	g
Glycerol gelatin	20.0	g
Polyethylene glycol 4000 q.s.	100.0	g

DETD [0106] A vaginal suppository formulation A gel preparation of **sildenafil** was prepared by admixing 2.5 g **sildenafil** with 100 g of high purity soybean lecithin (Sigma Chemical Company, St. Louis, Mo.).

Then, water was slowly added with. . .

DETD [0107] A liposomal solution is prepared as follows. Either an aqueous or oil-based solution of **tadalafil** and an optional additional active agent can be added to a liposomal mixture of, for example, 10 g of safflower. . . phosphatides, and 2.5 g of glycerin in a final volume of 100 ml (the remainder being water). Two mg of **tadalafil** may be added, and the resulting mixture then stirred until all components are dissolved. Liposomal solutions are particularly favored for. . .

CLM What is claimed is:

11. The pharmaceutical formulation of claim 10, wherein the Type V phosphodiesterase inhibitor is selected from **sildenafil** and acid addition salts thereof.

12. The pharmaceutical formulation of claim 8, wherein the Type V phosphodiesterase inhibitor is **tadalafil**.

15. The pharmaceutical formulation of claim 8, wherein the Type V phosphodiesterase inhibitor is **vardenafil**.

IT **139755-83-2**, Sildenafil **171596-29-5**, Tadalafil 330784-47-9
(phosphodiesterase inhibitors for treatment of female sexual dysfunction)

IT 53-43-0, Dehydroepiandrosterone 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 58-55-9, Theophylline, biological studies 58-74-2, Papaverine 76-43-7, Fluoxymesterone 315-37-7, Testosterone enanthate 363-24-6, Pge2 521-18-6, 5α-DihydroTestosterone 521-18-6D, 5α-DihydroTestosterone, esters 745-65-3, Pge1 855-22-1, 5α-DihydroTestosterone propionate 968-93-4, Testolactone 1045-69-8, Testosterone acetate 1164-91-6, 5α-DihydroTestosterone acetate 1169-49-9, Testosterone isobutyrate 2381-64-8 5704-03-0, Testosterone phenylacetate 5721-91-5, Testosterone caprate 5949-44-0, Testosterone undecanoate 6493-05-6, Pentoxifylline 6804-12-2, 5α-DihydroTestosterone undecanoate 19313-28-1, Pge0 28822-58-4, Ibmx 29925-17-5, Ro 20-1724 33776-88-4 37762-06-4, Zaprinast 51022-77-6, Etazolate 57076-71-8, Denbufylline 57361-80-5, Testosterone isocaprate 60719-84-8, Amrinone 61413-54-5, Rolipram 68475-42-3, Anagrelide 68550-75-4, Cilostamide 68728-46-1 73963-72-1, Cilostazol 74150-27-9, Pimobendan 78415-72-2, Milrinone 79030-08-3, Griseolic acid 79855-88-2, Trequinsin 81840-15-5, Vesnarinone 84490-12-0, Piroximone 86315-52-8, Isomazole 86798-59-6 89541-55-9 90880-94-7, Endothelium-derived relaxation factor 94192-59-3, Lixazinone 105165-22-8, Testosterone buciclate 112018-01-6, Bemoradan 114918-24-0, CP-77059 115344-47-3, Siguazodan 120223-30-5, EMD 54622 136145-07-8, Arofylline 151029-65-1 152814-89-6, RS-25344-00 **224785-90-4**, Vardenafil 330784-47-9 330785-79-0 488836-67-5 646505-32-0 646505-33-1
(phosphodiesterase inhibitors for treatment of female sexual dysfunction)

L16 ANSWER 17 OF 48 USPATFULL on STN
Full Text
AN 2003:325098 USPATFULL
TI Indole derivatives as pde5-inhibitors
IN Orme, Mark W, Seattle, WA, UNITED STATES
Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES
Schultze, Lisa M, Woodinville, WA, UNITED STATES
PI US 2003229080 A1 20031211
US 6878711 B2 20050412
SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).
IT **171596-29-5P** 171596-43-3P 422311-84-0P 422311-85-1P
(prepn. of pyrazino[1',2':1,6]pyrido[3,4-b]indole derivs. as phosphoesterase inhibitors for use as therapeutic agents)

L16 ANSWER 18 OF 48 USPATFULL on STN
Full Text
AN 2003:300913 USPATFULL

TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness
IN Neal, Gary W., Knoxville, TN, UNITED STATES
PI US 2003212139 A1 20031113
SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile** tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .
SUMM . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

L16 ANSWER 19 OF 48 USPATFULL on STN
Full Text
AN 2003:294885 USPATFULL
TI 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction
IN Wei, Edward T., Berkeley, CA, UNITED STATES
PI US 2003207903 A1 20031106
SUMM . . . during sexual arousal, and consequent erection, is a fact of male experience and does not require further description. In females, **clitoral stimulation** results in increased clitoral length and diameter, increased blood flow and tumescence of associated structures such as the labia folds.. . .
SUMM . . . 1980s, and now the use of transurethral alprostadil (Muse®), topical alprostadil with a enhancer of percutaneous absorption (Topiglan®), and oral **sildenafil** (Viagra®). The sales of Viagra® in 2001 are estimated to be U.S. $1.5 billion, but Viagra® has little effect on. . .

L16 ANSWER 20 OF 48 USPATFULL on STN
Full Text
AN 2003:294873 USPATFULL
TI Combination therapy for modulating the human sexual response
IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES
PI US 2003207891 A1 20031106
SUMM [0020] **Sildenafil**, (Viagra.TM., Pfizer, Inc.) 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl)phenyl]-1-methyl-3-proplyl-6,7-dihydro-1-H-pyrazolo[4,3-d]pyrimidin-7-one has also been shown to be useful as an oral treatment for male erectile dysfunction. [Martel et al., **Sildenafil**, Drugs of the Future, 22:138-143 (1997) which is incorporated in its entirety herein by reference.] See also, Boolell et al.,. . . (1996) and Boolell et al., Br.J. Urol., 78:257-261 (1996) both of which are incorporated herein in their entirety by reference. **Sildenafil** and related compounds are described in EP 0702555B1, which is incorporated herein by reference, is a phosphodiesterase V inhibitor and. . .
SUMM . . . the quality of the sexual response seen in patients, i.e., the relative rigidity of the erections achieved with for example **Sildenafil** is variable. [See, Boolell et al., Br. J. Urol., 78:257-261 (1996).] Therefore, there continues to exist a need in the. . .
SUMM . . . derivatives, amrinone, Vesnarinone, milrinone, rolipram, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones i.e., **Sildenafil**, (Viagra.TM.) also referred to as 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl)phenyl]-1-methyl-3propyl-6,7 dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one (see, Drugs of the Future22(2):138-143 (1997)), or 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3 -propyl-1H-pyrazolo[4,3-d]pyrimidine-5-yl)phenylsulphonyl]4-methylpiperazine (see, Boolell et al.,. . .
SUMM . . . of the present invention are preferably from about 5 mg to about 100 mg while preferred, doses of for example, **Sildenafil**, in the same tablet are preferably from about 5 mg to about 150 mg. Preferred doses of papaverine, when used. . .
SUMM . . . limited to xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and its citrate, and papaverine. Still other pharmaceutically active agents

useful in the compositions of the invention include dopaminergic antagonists,. . .

SUMM . . . milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones and, in particular, **Sildenafil**, and papaverine.

SUMM [0057] Other agents that are useful in combination with the alpha-adrenergic antagonist (e.g., phentolamine) and a phosphodiesterase inhibitor (**Sildenafil**) include α-adrenoceptor antagonists atipamezole, deacetylmoxisylyte HCl, and delequamine HCl. Other compositions include phentolamine and/or **Sildenafil** in combination with a dopaminergic agonist such as apomorpine.

DETD [0067] Exemplary formulations of a rapidly dissolving tablet that includes phentolamine mesylate and **Sildenafil** are set out below.

TABLE 1

	mg/tablet
Phentolamine Mesylate, USP	40
Sildenafil	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	162
Microcrystalline Cellulose, NF	120
Croscarmellose Sodium, NF	16

. . .

DETD [0074] Other illustrative formulations are set out below.

TABLE 2

	mg/tablet
Phentolamine Mesylate, USP	20
Sildenafil (Viagra .TM.)	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	182
Microcrystalline Cellulose, NF	120
Croscarmellose Sodium,. . .	

DETD . . . present invention also includes a chewable tablet formulation shown in Table 4.

TABLE 4

	mg/tablet
Phentolamine Mesylate, USP	40
Sildenafil	50
Silicon Dioxide, NF	12
Stearic Acid, NF	12
Lactose, NF	100
Sweetrex	298
Aspartame	40
ProSweet	8
Peppermint Flavor. . .	

DETD . . . inhibitors include xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and papaverine.

DETD [0093] **Sildenafil** has been shown to be effective at various doses including 25 mg and 50 mg (see Boolell et al., Br.. . .

DETD . . . comprises about 5 mg to about 100 mg phentolamine mesylate in combination with about 5 mg to about 125 mg **Sildenafil**.

DETD . . . administration of from about 5 mg to about 100 mg of phentolamine mesylate and about 5 to about 150 mg **Sildenafil** in a rapidly dissolving oral formulation of the present invention from about 1 minute to about 1 hour prior to,. . .

DETD [0100] As in the case of male sexual response, in the absence of any clinically diagnosed dysfunction in the **female erectile** response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . .

DETD . . . rapidly dissolving formulation as set out in Table 5 except that papaverine at the doses indicated below was substituted for **Sildenafil**. Dosages were as follows:

TABLE 5

	mg/tablet
Phentolamine Mesylate, (alone)	40
Papaverine (alone)	150
Phentolamine Mesylate plus Papaverine. . .	40

CLM What is claimed is:

4. The composition of claim 3 wherein the type V cyclic GMP-specific phosphodiesterase inhibitor is 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl)phenylsulfonyl]-4-methyl piperazine (**Sildenafil**).

5. A composition comprising from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl)phenylsulfonyl]-4-methyl piperazine (**Sildenafil**) and a pharmaceutically acceptable carrier.

. . . comprising from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7oxo-3-propyl-1H-pyrazolo[4,3[d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (**Sildenafil**) in an orally administrable tablet, the tablet having a disintegration time of less than about twenty minutes.

IT 50-60-2, Phentolamine 58-00-4, Apomorphine 58-74-2, Papaverine 65-28-1, Phentolamine mesylate 73-05-2, Phentolamine hydrochloride 37221-79-7, Vasoactive intestinal peptide **139755-83-2**, Sildenafil
(combination therapy for modulating human sexual response)

L16 ANSWER 21 OF 48 USPATFULL on STN
Full Text
AN 2003:271544 USPATFULL
TI Use of halogenated heterocyclic compounds in the treatment of sexual dysfunction and cardiovascular disease
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES
PI US 2003191152 A1 20031009
US 7041677 B2 20060509
SUMM [0013] **Sildenafil** citrate (Viagra) has also been utilized as a pharmacological treatment for impotence. However, **sildenafil** citrate has a lack of specificity for its target, enzyme phosphodiesterase 5 (PDE5), and exerts a definite inhibition on the. . . has been shown that the inhibition of PDE6 results in color vision defects as a side effect of treatment with **sildenafil** citrate. Furthermore, side effects such as flushing, headache, nasal congestion, and dyspepsia (heartburn) have also been associated with **sildenafil** citrate treatment of impotence. (See, Moreira et al., "Side-effect profile of **sildenafil** citrate (Viagra) in clinical practice," Urology, 56(3): 474-76 (2000)).
SUMM . . . flosequinan derivatives for improving blood flow and supply to female sexual organs, and more particularly, methods for the treatment of **female erectile** dysfunction. In selected embodiment the methods of the present invention comprise the utilization of these pharmaceutical compositions to induce clitoral. . .
DETD . . . of the penis and the associated facia which produce impotence, the inability to attain a sexually functional erection. In the **female** "**erectile** dysfunction" is associated with disorders (including but not limited to impaired blood flow to the clitoris) which impair or prevent. . .
DETD [0275] C. Diagnosis of **Female Erectile** Dysfunction
DETD [0282] D. Treatment of Male and **Female Erectile** Dysfunction

L16 ANSWER 22 OF 48 USPATFULL on STN
Full Text
AN 2003:181501 USPATFULL

TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PI US 2003125334 A1 20030703
US 6894050 B2 20050517
SUMM . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.
SUMM . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .
SUMM [0171] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimid in-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methyl piperazine (see EP-A-0463756);
SUMM [0174] (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .
SUMM [0175] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433); and. . .
SUMM [0176] According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
SUMM . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.
SUMM [0206] According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.
DETD . . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 23 OF 48 USPATFULL on STN
Full Text
AN 2003:153438 USPATFULL
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Willard M., JR., Mystic, CT, UNITED STATES
PI US 2003105106 A1 20030605
US 6825198 B2 20041130
SUMM . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.
SUMM . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .

SUMM [0233] More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

SUMM [0236] (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) -pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .

SUMM [0237] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);. . .

SUMM . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

SUMM . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

SUMM . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 24 OF 48 USPATFULL on STN
Full Text
AN 2003:134652 USPATFULL
TI Novel alpha adrenergic agents
IN Miller, Duane D., Germantown, TN, UNITED STATES
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF
PI US 2003092741 A1 20030515
US 6919357 B2 20050719

SUMM . . . included pain, risk of infection, inconvenience, and interference with spontaneity. Within the past few years, Pfizer's orally active product Viagra® (**sildenafil** citrate) has become a break-though treatment for ED. **Sildenafil** is a potent and selective cGMP-specific type 5 phosphodiesterase inhibitor and now represents the first line therapy for the treatment of ED. Despite **sildenafil**'s success, however, numerous patients have not been successfully treated. In addition, **sildenafil** must be administered significantly prior to sexual activity ruining spontaneity and numerous side effects have been reported. The most significant. . .

SUMM [0022] As in the case of male sexual response, in the absence of a clinically diagnosed dysfunction in the **female erectile** response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . .

L16 ANSWER 25 OF 48 USPATFULL on STN
Full Text
AN 2003:4131 USPATFULL
TI Combination therapy for modulating the human sexual response
IN Podolski, Joseph S., The Woodlands, TX, UNITED STATES
PI US 2003004170 A1 20030102

SUMM [0020] **Sildenafil**, (Viagra.TM., Pfizer, Inc.) 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl)phenyl]-1-methyl-3-proplyl-6,7-dihydro-1-H-pyrazolo[4,3-d]pyrimidin-7-one has also been shown to be useful as an oral treatment for male erectile dysfunction. [Martel et al., **Sildenafil**, Drugs of the Future, 22:138-143 (1997) which is incorporated in its entirety herein by reference.] See also, Boolell et al.,. . . and Boolell et al., Br. J. Urol, 78:257-261 (1996) both of which are incorporated herein in their entirety by reference. **Sildenafil** and related compounds are described in EP 0702555B1, which

is incorporated herein by reference, is a phosphodiesterase V inhibitor and. . .

SUMM . . . the quality of the sexual response seen in patients, i.e., the relative rigidity of the erections achieved with for example **Sildenafil** is variable. [See, Boolell et al, Br. J. Urol., 78:257-261 (1996).] Therefore, there continues to exist a need in the. . .

SUMM . . . derivatives, amrinone, Vesnarinone, milrinone, rolipram, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones i.e., **Sildenafil**, (Viagra.TM.) also referred to as 5-[2-ethoxy-5-(4-methylpiperazine-1-ylsulfonyl) phenyl]-1-methyl-3 propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one (see, Drugs of the Future22(2):138-143 (1997)), or 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidine-5-yl) phenylsulphonyl]4-methylpiperazine (see, Boolell et. . .

SUMM . . . of the present invention are preferably from about 5 mg to about 100 mg while preferred, doses of for example, **Sildenafil**, in the same tablet are preferably from about 5 mg to about 150 mg. Preferred doses of papaverine, when used. . .

SUMM . . . limited to xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and its citrate, and papaverine. Still other pharmaceutically active agents useful in the compositions of the invention include dopaminergic antagonists,. . .

SUMM . . . milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, the 5-(2'-alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones and, in particular, **Sildenafil**, and papaverine.

SUMM [0056] Other agents that are useful in combination with the alpha-adrenergic antagonist (e.g., phentolamine) and a phosphodiesterase inhibitor (**Sildenafil**) include α-adrenoceptor antagonists atipamezole, deacetylmoxisylyte HCl, and delequamine HCl. Other compositions include phentolamine and/or **Sildenafil** in combination with a dopaminergic agonist such as apomorpine.

DETD [0066] Exemplary formulations of a rapidly dissolving tablet that includes phentolamine mesylate and **Sildenafil** are set out below.

TABLE 1

	mg/tablet
Phentolamine Mesylate, USP	40
Sildenafil	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	162
Microcrystalline Cellulose, NF	120
Croscarmellose Sodium, NF	16

. . .

DETD [0073] Other illustrative formulations are set out below.

TABLE 2

	mg/tablet
Phentolamine Mesylate, USP	20
Sildenafil (Viagra .TM.)	50
Silicon Dioxide, NF	8
Stearic Acid, NF	4
Lactose, NF	182
Microcrystalline Cellulose, NF	120
Croscarmellose. . .	

DETD . . . present invention also includes a chewable tablet formulation shown in Table 4.

TABLE 4

	mg/tablet

Phentolamine Mesylate, USP	40
Sildenafil	50
Silicon Dioxide, NF	12
Stearic Acid, NF	12
Lactose, NF	100
Sweetrex	298
Aspartame	40
ProSweet	8
Peppermint Flavor. . .	

DETD . . . inhibitors include xanthine derivatives, amrinone, milrinone, rolipram, Vesnarinone, RO-1724, 8-methoxymethyl IBMX, cilostamide, Zapranast, MY-5445, M&B 22, 948, phenoximone, Dipyridamole, IBMX, **Sildenafil** and papaverine.

DETD [0092] **Sildenafil** has been shown to be effective at various doses including 25 mg and 50 mg (see Boolell et al, Br.. . .

DETD . . . comprises about 5 mg to about 100 mg phentolamine mesylate in combination with about 5 mg to about 125 mg **Sildenafil**.

DETD . . : administration of from about 5 mg to about 100 mg of phentolamine mesylate and about 5 to about 150 mg **Sildenafil** in a rapidly dissolving oral formulation of the present invention from about 1 minute to about 1 hour prior to,. . .

DETD [0099] As in the case of male sexual response, in the absence of any clinically diagnosed dysfunction in the **female erectile** response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . .

DETD . . . rapidly dissolving formulation as set out in Table 5 except that papaverine at the doses indicated below was substituted for **Sildenafil**. Dosages were as follows:

TABLE 5

mg/tablet

Phentolamine Mesylate, (alone)	40
Papaverine (alone)	150
Phentolamine Mesylate plus Papaverine. . .	40

CLM What is claimed is:

4. The composition of claim 3 wherein the type V cyclic GMP-specific phosphodiesterase inhibitor is 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3d]pyrimidin-5-yl) phenylsulfonyl]-4-methyl piperazine (**Sildenafil**).

5. A composition comprising from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d]pyrimidin-5-yl) phenylsulfonyl]-4-methyl piperazine (**Sildenafil**) and a pharmaceutically acceptable carrier.

. . . from about 5 mg to about 100 mg phentolamine and from about 5 mg to about 150 mg 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7oxo-3-propyl-1H-pyrazolo[4,3 [d]pyrimidin-5-yl)phenylsulfonyl]-4-methylpiperazine (**Sildenafil**) in an orally administrable tablet, the tablet having a disintegration time of less than about twenty minutes.

IT 50-60-2, Phentolamine 58-00-4, Apomorphine 58-74-2, Papaverine 65-28-1, Phentolamine mesylate 73-05-2, Phentolamine hydrochloride 37221-79-7, Vasoactive intestinal peptide **139755-83-2**, Sildenafil
(combination therapy for modulating human sexual response)

L16 ANSWER 26 OF 48 USPATFULL on STN
Full Text
AN 2002:338074 USPATFULL
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Heaton, Jeremy P. W., Gananoque, CANADA
Adams, Michael A., Kingston, CANADA

PI US 2002193442 A1 20021219
US 6756407 B2 20040629
SUMM . . . treatment of hot flashes, prevention of osteoporosis, and diminishment of the risk of heart disease. Estrogen replacement results in improved **clitoral sensitivity**, increased libido and decreased pain/burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, urinary frequency. . .
SUMM [0021] **Sildenafil** functions as a selective type 5 (i.e. c-GMP specific) phosphodiesterase inhibitor, and acts to decrease the metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. **Sildenafil** may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 27 OF 48 USPATFULL on STN
Full Text
AN 2002:301556 USPATFULL
TI Treatment of sexual dysfunction
IN Gonzalez, Maria Isabel, Cambridge, UNITED KINGDOM
Higginbottom, Michael, Cambridge, UNITED KINGDOM
Stock, Herman Thijs, Wijchen, NETHERLANDS
Pritchard, Martyn Clive, Huntingdon, UNITED KINGDOM
Pinnock, Robert Denham, Cambridgshire, UNITED KINGDOM
Van Der Graaf, Pieter Hadewijn, Kent, UNITED KINGDOM
Naylor, Alisdair Mark, Kent, UNITED KINGDOM
Wayman, Christopher Peter, Kent, UNITED KINGDOM
PI US 2002169101 A1 20021114
SUMM . . . be administered orally, therefore obviating the disadvantages associated with i.c. administration. One such compound that is currently being manufactured is **sildenafil** (Viagra).
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**. Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of pre-, peri- and postmenopausal. . .
DETD . . . treatment of sexual dysfunction include alprostadil or phentolamine, NO (nitric oxide) enhancers such as L-arginine, and PDE5 inhibitors such as **sildenafil** or a pharmaceutically acceptable salt thereof (Scrip's Complete Guide to Women's Healthcare, p.194-205, 2000)(Sachs B. D., 2000, Benet and Melman,. . .
DETD [0460] 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);
DETD [0471] 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo [5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433;. . .
DETD . . . Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805.

L16 ANSWER 28 OF 48 USPATFULL on STN
Full Text
AN 2002:295077 USPATFULL
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Heaton, Jeremy P. W., Kingston, CANADA
Adams, Michael A., Kingston, CANADA
PI US 2002165122 A1 20021107
SUMM . . . treatment of hot flashes, prevention of osteoporosis, and diminishment of the risk of heart disease. Estrogen replacement results in improved **clitoral sensitivity**, increased libido and decreased pain/burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, urinary frequency. . .
SUMM [0020] **Sildenafil** functions as a selective type 5 (i.e. c-GMP specific) phosphodiesterase inhibitor, and acts to decrease the

metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. **Sildenafil** may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 29 OF 48 USPATFULL on STN
Full Text
AN 2002:266337 USPATFULL
TI The treatment of sexual dysfunction with enantiomers
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES
Sramek, John, Irvine, CA, UNITED STATES
PI US 2002147217 A1 20021010
SUMM [0012] **Sildenafil** citrate (Viagra) has also been utilized as a pharmacological treatment for impotence. However, **sildenafil** citrate has a lack of specificity for its target, enzyme phosphodiesterase 5 (PDE5), and exerts a definite inhibition on the. . . has been shown that the inhibition of PDE6 results in color vision defects as a side effect of treatment with **sildenafil** citrate. Furthermore, side effects such as flushing, headache, nasal congestion, and dyspepsia (heartburn) have also been associated with **sildenafil** citrate treatment of impotence. (See, Moreira et al., "Side-effect profile of **sildenafil** citrate (Viagra) in clinical practice," Urology, 56(3): 474-76 (2000)).
DETD DIAGNOSIS OF **FEMALE ERECTILE** DYSFUNCTION
DETD TREATMENT OF MALE AND **FEMALE ERECTILE** DYSFUNCTION
DETD . . . example, a biochemical assay was performed to test the percentage of phosphodiesterase 6 (PDE6) inhibition of various molar concentrations of **sildenafil** citrate (Viagra) as compared to that of a 100 μM concentration of a racemic mixture of flosequinan as follows.

L16 ANSWER 30 OF 48 USPATFULL on STN
Full Text
AN 2002:262363 USPATFULL
TI Carboline derivatives as cGMP phosphodiesterase inhibitors
IN Bombrun, Agnes, Monnetier Mornex, FRANCE
Gellibert, Fran.cedilla.oise, Paris Cedex, FRANCE
PI US 6462047 B1 20021008
WO 2000015639 20000323
SUMM . . . diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, peptic ulcer, male and **female erectile** dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).
SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, **sildenafil**, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR6##
SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

L16 ANSWER 31 OF 48 USPATFULL on STN
Full Text
AN 2002:243641 USPATFULL
TI Treatment of erectile dysfunction
IN Mills, Thomas M., Augusta, GA, UNITED STATES
Wingard, Christopher J., Augusta, GA, UNITED STATES
Webb, R. Clinton, Matinez, GA, UNITED STATES
Lewis, Ronald W., Augusta, GA, UNITED STATES
Chitaley, Kanchan, Augusta, GA, UNITED STATES
PI US 2002132832 A1 20020919
AB . . . to the treatment of sexual dysfunction by inhibition of vasoconstriction leading to the relaxation of smooth muscles in male or **female erectile** tissue. In one aspect, the invention comprises methods for treating male and female sexual dysfunction which comprises administering a composition. . .
SUMM . . . of nitric oxide (NO), enabling relaxation of blood vessels in the cavernosal circulation during sexual stimulation. For example, the compound **sildenafil** (Viagra) is a type 5 phosphodiesterase inhibitor that potentiates the effects of local release of NO, thereby resulting

in vascular smooth muscle relaxation. Studies have found **sildenafil** to have an overall 60% efficacy rate in the promotion of NO-mediated cavernosal vasorelaxation (Virag, R., Urology 54, 1073-77, 1999). Still, in those patients with severe erectile dysfunction (such as that resulting from diabetes or prostate surgery), **sildenafil** treatment was associated with a modest satisfaction rate (Jarow, I. P. et al., J. Urology, 102, 722-725, 1999). Moreover, only 30% of patents studied chose **sildenafil** treatment alone (Virag, R., 1999).

SUMM . . . include U.S. Pat. No. 6,087,362, which describes treatment of sexual dysfunction by an oral therapy of administration of apomorphine and **sildenafil** which is directed to minimizing the side effects of each agent. Other patents describing treatments for sexual dysfunction include U.S.. . .

DETD . . . of blood. Several drugs used to treat erectile dysfunction work by prolonging the effect of NO. For example, the compound **sildenafil** (Viagra) is a type 5 phosphodiesterase inhibitor used for the treatment of erectile dysfunction. Phosphodiesterase type 5 (PDE5) is responsible. . . of cGMP in the corpus cavernosum. Thus, when sexual stimulation results in local release of NO, inhibition of PDE5 by **sildenafil** (Viagra) maintains increased levels of cGMP in the corpus cavernosum, resulting in vascular smooth muscle relaxation.

DETD . . . of phentolamine. Also, U.S. Pat. No. 6,087,362 describes the treatment of sexual dysfunction by an oral regimen of apomorphine and **sildenafil**, and U.S. Pat. No. 6,007,824 describes treatment of sexual dysfunction using an oral dosage of L-arginine, ginseng and Zizyphi fructus.

L16 ANSWER 32 OF 48 USPATFULL on STN
Full Text
AN 2002:133870 USPATFULL
TI Composition to boost libido
IN Reyes, Joe, Troy, MI, UNITED STATES
PI US 2002068728 A1 20020606
US 6803060 B2 20041012

SUMM . . . sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. See "Oral **Sildenafil** in the Treatment of Erectile Dysfunction", New England Journal of Medicine, 338:20:1397 (1998). There are numerous causes of male erectile. . .

SUMM . . . male erectile dysfunction, including vacuum-constriction devices, intracavernosal injections of vasoactive agents, transurethral delivery of prostaglandin E_1 (alprostadil), oral administration of **sildenafil** citrate (Viagra® available from Pfizer), implantation of penile prostheses, and venous or arterial surgery. Most of these treatments involve painful. . . candidates for one or more of these treatments as a result of their physiological condition. For example, oral admistration of **sildenafil** citrate is contraindicated for individuals currently taking organic nitrates, such a nitroglycerine. See "VIAGRA® (**sildenafil** citrate) Tablets", Pfizer Labs, 7 (1998).

DETD . . . such as Catuba Bark, a compound to increase blood flow to the pelvic area (in the preferred embodiment this causes **clitoral sensitivity**), such as Muria Puama, a compound to cause the body to produce natural estrogen, such as Wild Yam Root, a. . .

CLM What is claimed is:
8. The composition according to claim 2, wherein said estrogen producing compound causes **clitoral sensitivity**.

L16 ANSWER 33 OF 48 USPATFULL on STN
Full Text
AN 2002:122643 USPATFULL
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Adams, Michael A., Kingston, CANADA
Heaton, Jeremy P. W., Gananoque, CANADA
PI US 6395744 B1 20020528

SUMM . . . treatment of hot flashes, prevention of osteoporosis, and diminishment of the risk of heart disease. Estrogen replacement results in improved **clitoral sensitivity**, increased libido and decreased pain/burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, urinary frequency. . .

SUMM **Sildenafil** functions as a selective type 5 (i.e. c-GMP specific)

phosphodiesterase inhibitor, and acts to decrease the metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. **Sildenafil** may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 34 OF 48 USPATFULL on STN
Full Text
AN 2002:8529 USPATFULL
TI METHODS, COMPOSITIONS, AND KITS FOR ENHANCING FEMALE SEXUAL DESIRE AND RESPONSIVENESS
IN NEAL, GARY W., KNOXVILLE, TN, UNITED STATES
PI US 2002004529 A1 20020110
SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile** tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .
SUMM . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

L16 ANSWER 35 OF 48 USPATFULL on STN
Full Text
AN 2001:212470 USPATFULL
TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness
IN Neal, Gary W., Knoxville, TN, United States
PI US 2001044467 A1 20011122
US 6593369 B2 20030715
SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile** tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .
SUMM . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

L16 ANSWER 36 OF 48 USPATFULL on STN
Full Text
AN 2001:158350 USPATFULL
TI Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
IN Scott, Nathan Earl, 610 Laguna Rd., Fullerton, CA, United States 92835
PI US 6291528 B1 20010918
SUMM Most recently Pfizer has made **sildenafil** citrate available in oral dosages as a treatment for impotence under the trade name, Viagra®. However, Viagra® is counter indicated. . . addition, a new warning has been added to labeling for Viagra® warning of a possible occurrence of priapism. Also since **sildenafil** citrate is administered orally, the effect of the drug is systemic and not restricted, as in direct delivery to the. . .
DETD . . . appears to be associated with deeper pelvic contractions and to be more pleasurable from "G-spot" stimulation than orgasm resulting from **clitoral stimulation** alone.

L16 ANSWER 37 OF 48 USPATFULL on STN
Full Text
AN 2000:150177 USPATFULL
TI Chemical compounds
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France
LaBaudiniere, Richard Frederick, Collegeville, PA, United States
PI US 6143757 20001107
SUMM . . . thrombocythemia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and

female erectile dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome or IBS).

SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, **sildenafil**, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR5## and has shown efficacy in oral. . .

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

L16 ANSWER 38 OF 48 USPATFULL on STN
Full Text
AN 2000:150166 USPATFULL
TI Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
IN Daugan, Alain Claude-Marie, Marly le Roi Cedex, France
Gellibert, Francoise, Marly le Roi Cedex, France
PI US 6143746 20001107

SUMM . . . thrombocythemia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).

SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, **sildenafil**, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR12## and has shown efficacy in oral. . .

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

IT

171488-01-0P	171488-02-1P	171488-03-2P	171488-04-3P	171488-05-4P
171488-06-5P	171488-07-6P	171488-08-7P	171488-09-8P	171488-10-1P
171488-11-2P	171488-12-3P	171488-13-4P	171488-14-5P	171488-15-6P
171488-16-7P	171488-17-8P	171488-18-9P	171488-19-0P	171488-20-3P
171488-21-4P	171488-22-5P	171488-23-6P	171488-24-7P	171488-25-8P
171488-26-9P	171488-27-0P	171488-28-1P	171488-29-2P	171488-30-5P
171488-31-6P	171488-32-7P	171488-33-8P	171488-34-9P	171488-35-0P
171488-36-1P	171488-37-2P	171488-38-3P	171488-39-4P	171488-40-7P
171488-41-8P	171488-42-9P	171488-43-0P	171488-44-1P	171488-45-2P
171488-46-3P	171488-47-4P	171488-48-5P	171488-49-6P	171488-50-9P
171488-51-0P	171488-52-1P	171488-53-2P	171488-54-3P	171488-55-4P
171488-56-5P	171488-57-6P	171488-58-7P	171488-59-8P	171488-60-1P
171488-61-2P	171488-62-3P	171488-63-4P	171488-64-5P	171488-65-6P
171488-66-7P	171488-67-8P	171488-68-9P	171488-69-0P	171488-70-3P
171488-71-4P	171488-72-5P	171488-73-6P	171488-74-7P	171488-75-8P
171488-76-9P	171488-77-0P	171488-78-1P	171488-79-2P	171488-80-5P
171488-81-6P	171488-82-7P	171488-84-9P	171488-85-0P	171488-86-1P
171488-87-2P	171488-88-3P	171488-89-4P	171488-90-7P	171488-91-8P
171488-92-9P	171488-94-1P	171488-95-2P	171488-96-3P	171488-97-4P
171488-98-5P	171488-99-6P	171489-01-3P	171489-02-4P	171489-03-5P
171489-04-6P	171596-27-3P	171596-28-4P	**171596-29-5P**	
171596-30-8P	171596-31-9P	171596-32-0P	171596-33-1P	171596-34-2P
171596-35-3P	171596-36-4P	171596-37-5P	171596-38-6P	171596-39-7P
171596-40-0P	187935-15-5P	187939-81-7P	303984-31-8P	303984-32-9P
303984-33-0P	303984-34-1P	303984-35-2P	303984-36-3P	303984-37-4P

(tetracyclic cyclic GMP-specific phosphodiesterase inhibitors and their use in disease treatment)

L16 ANSWER 39 OF 48 USPATFULL on STN
Full Text
AN 2000:37808 USPATFULL
TI Carboline derivatives
IN Bombrun, Agnes, Paris, France
PI US 6043252 20000328

SUMM . . . diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable

bowel syndrome or IBS).

SUMM . . . heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, **sildenafil**, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure: ##STR8## and has shown efficacy in oral. . .

SUMM . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

L16 ANSWER 40 OF 48 USPAT2 on STN
Full Text

AN 2005:38129 USPAT2

TI 5-HT receptor ligands and uses thereof

IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Jr., Willard M., Mystic, CT, UNITED STATES

PI US 6995159 B2 20060207

DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.

DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .

DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);

DETD (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6, 1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .

DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5, 1-f[]1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5, 1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);. . .

DETD . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.

DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.

DETD . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.

DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.

DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 41 OF 48 USPAT2 on STN
Full Text

AN 2003:325098 USPAT2

TI Indole derivatives as PDE5-inhibitors

IN Orme, Mark W., Seattle, WA, UNITED STATES
Sawyer, Jason Scott, Indianapolis, IN, UNITED STATES
Schultze, Lisa M., Woodinville, WA, UNITED STATES

PI US 6878711 B2 20050412
WO 2002036593 20020510

DETD . . . prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm

labor, benign prostatic hypertrophy, male and **female erectile** dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

IT **171596-29-5P** 171596-43-3P 422311-84-0P 422311-85-1P
(prepn. of pyrazino[1',2':1,6]pyrido[3,4-b]indole derivs. as phosphoesterase inhibitors for use as therapeutic agents)

L16 ANSWER 42 OF 48 USPAT2 on STN
Full Text
AN 2003:271544 USPAT2
TI Use of monochlorofosequinan in the treatment of sexual dysfunction
IN Cutler, Neal R., Los Angeles, CA, UNITED STATES
PI US 7041677 B2 20060509
SUMM **Sildenafil** citrate (Viagra) has also been utilized as a pharmacological treatment for impotence. However, **sildenafil** citrate has a lack of specificity for its target, enzyme phosphodiesterase 5 (PDE5), and exerts a definite inhibition on the. . . has been shown that the inhibition of PDE6 results in color vision defects as a side effect of treatment with **sildenafil** citrate. Furthermore, side effects such as flushing, headache, nasal congestion, and dyspepsia (heartburn) have also been associated with **sildenafil** citrate treatment of impotence. (See, Moreira et al., "Side-effect profile of **sildenafil** citrate (Viagra) in clinical practice," Urology, 56(3): 474-76 (2000)).
SUMM . . . flosequinan derivatives for improving blood flow and supply to female sexual organs, and more particularly, methods for the treatment of **female erectile** dysfunction. In selected embodiment the methods of the present invention comprise the utilization of these pharmaceutical compositions to induce clitoral. . .
DETD . . . of the penis and the associated facia which produce impotence, the inability to attain a sexually functional erection. In the **female** "**erectile** dysfunction" is associated with disorders (including but not limited to impaired blood flow to the clitoris) which impair or prevent. . .
DETD C. Diagnosis of **Female Erectile** Dysfunction
DETD D. Treatment of Male and **Female Erectile** Dysfunction

L16 ANSWER 43 OF 48 USPAT2 on STN
Full Text
AN 2003:181501 USPAT2
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, UNITED STATES
Novomisle, William A., Stonington, CT, UNITED STATES
Welch, Jr., Willard M., Mystic, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
DaSilva-Jardine, Paul A., Killingworth, CT, UNITED STATES
Garigipati, Ravi S., South Glastonbury, CT, UNITED STATES
Liu, Kevin K., East Lyme, CT, UNITED STATES
PI US 6894050 B2 20050517
DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.
DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .
DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methyl piperazine (see EP-A-0463756);
DETD (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .
DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application

WO99/24433); and. . .
DETD According to a further aspect the present invention provides a composition for the treatment of MED comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.
DETD According to a further aspect, the present invention provides a composition for the treatment of FSD comprising 6'-(3-Chloro-benzyloxy)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl and **sildenafil**.
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.
DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 44 OF 48 USPAT2 on STN
Full Text
AN 2003:153438 USPAT2
TI 5-HT receptor ligands and uses thereof
IN Chiang, Phoebe, East Lyme, CT, United States
Novomisle, William A., Stonington, CT, United States
Welch, Jr., Willard M., Mystic, CT, United States
PI US 6825198 B2 20041130
DETD . . . genitalia. They consist of two types of formulation, oral or sublingual medications (Apomorphine, Phentolamine, phosphodiesterase type 5 (PDE5) inhibitors, e.g. **Sildenafil**), and prostaglandin (PGE_1) that are injected or administered transurethrally in men and topically to the genitalia in women.
DETD . . . alone or via combination therapy based on compound(s) of the present invention and a cGMP PDE5i, such as for example **sildenafil**. Patients with mild to moderate MED should benefit from combined treatment based on compound(s) of the present invention alone or. . .
DETD More preferred are compounds such as, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (**sildenafil**) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756);
DETD (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351, **tadalafil**), i.e. the compound of examples 78 and 95 of published international application WO95/19978, as well as the compound of examples. . .
DETD 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (**vardenafil**) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine (i.e. the compound of examples 20, 19, 337 and 336 of published international application WO99/24433);. . .
DETD . . . aspect the present invention provides a composition for the treatment of MED comprising a compound of the present invention and **sildenafil**.
DETD . . . 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and more preferably a PDE5 inhibitor (as described hereinabove), most preferably **sildenafil**.
DETD . . . aspect, the present invention provides a composition for the treatment of FSD comprising a compound of the present invention and **sildenafil**.
DETD . . . to increased vaginal lubrication via plasma transudation, increased vaginal compliance (relaxation of vaginal smooth muscle) and increases in vaginal and **clitoral sensitivity**.
DETD . . . (Berman, J., Goldstein, I., Werbin, T. et al. (1999a). Double blind placebo controlled study with crossover to assess effect of **sildenafil** on physiological parameters of the female sexual response. J. Urol., 161, 805; Goldstein, I. & Berman, J. R. (1998). Vasculogenic. . .

L16 ANSWER 45 OF 48 USPAT2 on STN
Full Text

AN 2003:134652 USPAT2
TI α adrenergic agents
IN Miller, Duane D., Germantown, TN, UNITED STATES
Hong, Seoung-Soo, Cheongju, KOREA, REPUBLIC OF
PI US 6919357 B2 20050719
SUMM . . . included pain, risk of infection, inconvenience, and interference with spontaneity. Within the past few years, Pfizer's orally active product Viagra® (**sildenafil** citrate) has become a break-though treatment for ED. **Sildenafil** is a potent and selective cGMP-specific type 5 phosphodiesterase inhibitor and now represents the first line therapy for the treatment of ED. Despite **sildenafil**'s success, however, numerous patients have not been successfully treated. In addition, **sildenafil** must be administered significantly prior to sexual activity ruining spontaneity and numerous side effects have been reported. The most significant. . .
DETD As in the case of male sexual response, in the absence of a clinically diagnosed dysfunction in the **female erectile** response, the methods of the present invention may be used to enhance the normal female sexual response. The "on demand". . .

L16 ANSWER 46 OF 48 USPAT2 on STN
Full Text
AN 2002:338074 USPAT2
TI Method and compositions for the treatment or amelioration of female sexual dysfunction
IN Heaton, Jeremy P. W., Gananoque, CANADA
Adams, Michael A., Kingston, CANADA
PI US 6756407 B2 20040629
SUMM . . . treatment of hot flashes, prevention of osteoporosis, and diminishment of the risk of heart disease. Estrogen replacement results in improved **clitoral sensitivity**, increased libido and decreased pain/burning during intercourse. Local or topical estrogen application relieves symptoms of vaginal dryness, burning, urinary frequency. . .
SUMM **Sildenafil** functions as a selective type 5 (i.e. c-GMP specific) phosphodiesterase inhibitor, and acts to decrease the metabolism of c-GMP, the. . . safe and effective in improving erectile duration and rigidity. In females, nitric oxide/NOS exists in human vaginal and clitoral tissue. **Sildenafil** may prove useful alone, or possibly in combination with other vasoactive agents for the treatment of vasculogenic female sexual dysfunction.. . .

L16 ANSWER 47 OF 48 USPAT2 on STN
Full Text
AN 2002:133870 USPAT2
TI Composition to boost libido
IN Reyes, Joe, 1175 Chicago Rd., Troy, MI, United States 48083
PI US 6803060 B2 20041012
SUMM . . . sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. See "Oral **Sildenafil** in the Treatment of Erectile Dysfunction", New England Journal of Medicine, 338:20:1397 (1998). There are numerous causes of male erectile. . .
SUMM . . . male erectile dysfunction, including vacuum-constriction devices, intracavernosal injections of vasoactive agents, transurethral delivery of prostaglandin E_1 (alprostadil), oral administration of **sildenafil** citrate (Viagra®[1] available from Pfizer), implantation of penile prostheses, and venous or arterial surgery. Most of these treatments involve painful. . . candidates for one or more of these treatments as a result of their physiological condition. For example, oral admistration of **sildenafil** citrate is contraindicated for individuals currently taking organic nitrates, such a nitroglycerine. See "VIAGRA® (**sildenafil** citrate) Tablets", Pfizer Labs, 7 (1998).
DETD . . . such as Catuba Bark, a compound to increase blood flow to the pelvic area (in the preferred embodiment this causes **clitoral sensitivity**), such as Muria Puama, a compound to cause the body to produce natural estrogen, such as Wild Yam Root, a. . .

L16 ANSWER 48 OF 48 USPAT2 on STN
Full Text
AN 2001:212470 USPAT2
TI Methods, compositions, and kits for enhancing female sexual desire and responsiveness

IN Neal, Gary W., Knoxville, TN, United States
PI US 6593369 B2 20030715
SUMM . . . It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the **female erectile** tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of. . .
SUMM . . . but not limited to caffeine, aminophylline, theophylline, amrinone, milrinone, vesnarinone, vinpocetine, pemobendan, cilostamide, enoximone, peroximone, rolipram, R020-1724, zaniprast, dipyridamole, and **sildenafil**, may also be effective in enhancing the efficacy of the present method and for prolonging the effect;

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	121.17	146.66

STN INTERNATIONAL LOGOFF AT 21:16:57 ON 06 APR 2007